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61. 0 INTRODUCTION
1. 1 GENERATION OF ANTIBODIES
Mammalian B lymphocytes are formed first in the liver during fetal life but the bone
marrow becomes the site of lymphopoeisis after birth and remains so throughout adult
life (Rolink and Melchers, 1991; Kincade, 1987). Genes expressed in B lymphocytes
encode the immunoglobulin (Ig) molecule. The monomeric immunoglobulin is
composed of two identical heavy (H) and light (L) polypeptide chains. The amino-
terminal domain of each polypeptide chain consists of a variable region whilst the
carboxy-terminus contains the constant domain(s). Pairing together of a variable light
and heavy chain region form the antigen-combining site responsible for antigen-
antibody interactions. Each separate variable domain has three areas of high amino acid
sequence variability (hypervariable regions) known as complementarity-determining
regions (CDR) interspersed by regions of relatively constant amino acid sequence
termed framework regions (FR) (Kabat et. al., 1991). CDR3 is the region of greatest
variability.
The immunoglobulin heavy chain variable region segment is encoded by a variable
(VH), diversity (D), and a joining (JH) gene segments while the light chain variable
region is encoded by a variable (VL), and joining (JL) segment. A site-specific
recombination reaction known as VH(D)JH recombination brings gene segments present
in the germline together to form a functional B cell receptor gene that encodes surface
immunoglobulin in a ’virgin’ B cell. Virgin B cells in the primary immune repertoire
expressing germline encoded antibodies of the IgM isotype migrate from the primary
lymphoid organs (fetal liver, fetal and adult bone marrow) into secondary lymphoid
organs - spleen, lymph nodes - where contact with antigen, further differentiation into
plasma cells may result in the secretion of either IgG, IgA, or IgE isotypes. The
significance of isotypes of antibodies is demonstrated in the generation of IgG
antibodies which are usually somatically mutated in the variable region and have higher
affinities for antigen than IgM (Potter and Capra, 1995).
1. 2 VH(D)JH RECOMBINATION AND THE HUMAN IMMUNOGLOBULIN
LOCI
Assembly of immunoglobulin genes by the VH(D)JH recombination process machinery
under the influence of recombination activating genes (RAGs) brings different gene
elements of the V region together to create considerable diversity (termed combinatorial
diversity) in the antibody molecule. Additional diversity can occur by random insertion
or deletion of a few nucleotides at the junctions of the segments. This is termed
junctional diversity. Studies involving the development of the primary immune
7repetoire expressed in normal individuals, fetal B lymphocytes, and autoantibodies have
led to the identification of immunoglobulin  gene families. Sequence analysis of
individual gene seqments, and mapping of their chromosomal locations have helped to
determine which immunoglobulin gene segments are used in the development of the
normal immunoglobulin repetoire (Matsuda et. al., 1998; Cook and Tomlinson, 1995).
1. 2. 1 The human antibody IgH locus
The human antibody variable heavy chain locus (VH, D and JH genes) is located on
chromosome 14q32.3 (Cox et. al., 1982). Sequence analysis, pulse-field gel
electrophoresis mapping (PFGE), deletion mapping and cloning suggest that the human
VH locus contains 51 functional VH gene segments (Cook and Tomlinson, 1995;
Tomlinson, 1997). Another study reported the existence of 44 functional VH genes
(Matsuda et. al., 1998). The difference in the number of functional VH genes in these
two independent studies is attributed to an insertion/deletion polymorphic region which
when present results in the increase of some functional genes. The human VH genes are
grouped into 7 families (van Dijk et. al., 1993). Belonging to a particular Ig (VH) family
means sharing at least 80% nucleotide sequence homology while genes with less than
70% homology are members of a different family. However, a unique set of VH
segments which share high homology (72 - 82%) with VH1 but differ at a clustered
region between framework 2 (FR2) and FR3 has been placed into a different family, the
VH7 family (Schroeder et. al., 1990). Among the 51 known functional VH segments,
VH3 is the largest with 22 members, VH4 and VH1 has 11 each, VH2 has 3 members,
VH5 has 2, and VH6 and VH7 has 1 member each (Tomlinson, 1997). There are several
family-specific conserved regions within the human germline VH segments. These
family-specific sequences were found in codons 9 - 30 in FR1 and 60 - 85 of FR3
(Kabat et. al., 1991; Tomlinson et. al., 1992 Matsuda et. al., 1993). The conservation of
sequences is not limited to only the framework regions. Complementarity determining
region 2 (CDR2), one of the regions showing hypervariability, also displays some
amount of family-specific conservation. Codons 60 - 65 in the 3’ portion of CDR2 are
conserved in a family-specific way (Honjo and Matsuda, 1995). 25 functional human D
gene segments are grouped into 7 families whilst 6 JH human gene segments are known
(Tomlinson, 1997).
1. 2. 2 The human variable light chain locus
The human antibody variable light chain loci (VL and JL genes) are derived from either
the kappa (κ) locus on chromosome 2p11-12 (Malcolm et. al., 1982) or the lambda (λ)
locus on chromosome 22q11.2 (de la Chapelle et. al., 1983). In humans, 60% of
immunoglobulin light chains are kappa while 40% are lambda. A total of 40 human Vκ
8gene segments have been divided into 7 families. The human Vλ locus is divided into 10
families with a total of 38 functional genes (Williams et. al., 1996; Tomlinson 1997).
At the murine light chain locus, λ gene rearrangement always occurs after κ genes fail
to rearrange (Retter and Nemazee, 1998). Thus if an appropriate κ gene is not
assembled, rearrangement at the λ locus often follows.   
1. 3  PHAGE DISPLAY TECHNOLOGY
Nearly eighty years after the discovery of antibodies by Emil Behring in 1894, Köhler
and Milstein (1975) first described the production of monoclonal antibodies by
hybridoma technology which has been of immense use as therapeutic immunoreagents,
and in bio-medical research (Verhoeyen and Windust, 1996).
Though monoclonal antibody production offers an unlimited supply of specific rodent
antibodies, the hybridoma technique has been much less successful for human
monoclonal antibodies (James and Bell, 1987). A major drawback in the use of rodent
antibodies in therapy of human antibodies is the problem of human antimouse antibody
response which limits their use. A solution to the problem of immunogenicity of rodent
monoclonal antibodies in humans would be to produce human antibodies directly from
humans since it is technically much more difficult to immortalize human B cells to
human tissue antigens than making (many) rodent antibodies, and also unethical to
immunize human donors in human monoclonal antibody production. Recent advances
in molecular biology and protein engineering has opened new vistas in biological
research resulting in recombinant antibody technology that offers new
immunotherapeutic opportunities. The new technology involves cloning of the human
immunoglobulin gene repertoire comprising heavy chain and light chain genes,
recombining them randomly to give a combinatorial antibody library, and expressing
the antibodies on the surface of microorganisms.
1.3.1 Antibody production by combinatorial libraries
The display of peptides on the surface of filamentous phages (Smith, 1985), provided a
significant beginning to phage antibody display technology. The first development
toward combinatorial antibody libraries involved cloning the repertoire of VH genes
from an immunized mouse spleen into bacteriophage lambda (Sastry et. al., 1989).
Shortly afterwards, Huse et. al. (1989), produced the first combinatorial antibody
library by producing murine catalytic antibodies in lambda phage. PCR sequences of
heavy (Fd; VH + CH1) and light chains from mouse RNA were cloned into separate
lambda vectors. Vector DNA immediately downstream of the cloned mouse heavy
chain DNA was digested away and similarly, vector sequences upstream of the mouse
9light chain DNA were also cleaved. The two vector arms were digested at a common
central restriction site using a common restriction enzyme and religated, such that a
random pair of heavy and light chain was combined irrespective of their original pairing
in the spleen cells, to give the first random combinatorial antibody library. Screening of
the library for clones expressing functional Fabs (VH1-CH1 + VL-CL) were done by the
adsorption of Fabs onto nitrocellulose filters and incubated with labeled antigen for
detection of specific clones. Seperate heavy and light chain libraries were negative.
1.3.2 Production of antibody fragments by Phage Display
The screening procedure of the lambda phage system imposed limitations to the
effectiveness of the technique. Screening a library of say 5 x 108 antibodies would
require a minimum of 10,000 filter lifts (at 50,000 plaques per filter lift) making the
screening extremely laborious. Besides, the antigen must be available in large quantities
and be readily amenable to radioactive labeling, and should also not significantly stick
to filters in the absence of antibody (Burton and Barbas, 1994). This imposes
restrictions on for example, membrane-bound antigens, and hampers the effectiveness
of the lambda phage system.
A new technique which was based on Smith’s display of peptides on the surface of
filamentous phages was utilized. Foreign DNA fragments were ligated to the minor coat
protein III gene of filamentous phages, creating a `fusion phage´. The peptides were
shown to bind immobilized antibodies, and led to easy screening of libraries for binding
to ligands and antibodies. McCafferty et. al. (1990), displayed single chain variable
domain fragment (scFv) antibodies on the surface of filamentous phages. ScFv consists
of a heavy chain and light chain variable domains connected on the same polypeptide
chain by a flexible oligopeptide linker. The use of filamentous phage genome as a
cloning vehicle has some limitations. Since large inserts are known to adversely effect
the infectivity of the phages, the risk of the library being populated by rapidly growing
deletion mutants was high (Little et. al. 1997). Besides, it is difficult to prepare the
double-stranded DNA necessary for cloning, hence phagemid systems were introduced
as an attractive alternative to cloning directly into the phage genome (Burton and
Barbas, 1994). The display of peptides on phages was applied to proteins. (Kang et. al.,
1991a; Breitling et. al. 1991; Chang et. al., 1991; Duchosal et. al., 1992) described the
use of phagemid vectors in combination with helper phage rescue for the construction
and rapid analysis of combinatorial antibody libraries.
Phagemids are plasmids that contain filamentous bacteriophage origin of replicaton but
none of the genes required for replication, DNA packaging, and assembly of phage
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particles. They are double-stranded, making cloning easier, and allow 100-fold higher
efficiencies of transformation compared to phage vectors (Verhoeyen and Windust,
1996; Little et. al., 1995). Phagemids can be packaged into phage particles by ’rescue’
with helper phages such as VCSM13 (Stratagene, La Jolla, Ca., USA) that provides all
the phage proteins necessary for replication, DNA packaging and assembly of phage
particles. The helper phage itself is unable to package its own genome due to a defective
origin of replication (Burton and Barbas, 1994). Therefore, cells transformed with a
phagemid are infected with a helper phage to provide proteins required for replication
and packaging single-stranded phagemid DNA into the filamentous phage particle. The
mature phage with the potential to bind antigen displays statistically one copy of Fab-
cpIII fusion protein and 3-4 copies of the native cpIII protein which mediates phage
infectivity (Fig. 1.0). In a most recent publication, Rondot et. al. (2001) reports a
considerable increase in the fraction of phage particles displaying antibody fragments
by the use of a newly-developed helper phage (hyperphage), and a mutated E. coli
strain.
1.3.3 Phagemid pComb3H
The phagemid pComb3H (Fig. 1.1) used in this study is a derivative of the original
pComb3 phagemid vector (Barbas et. al., 1991). The main features of pComb3 are that
it contains both the origin of replication of the multicopy plasmid ColE1 and the origin
of replication of the filamentous bacteriophage f1. The phagemid also contains the
enzyme beta-lactamase gene that confers ampicillin (carbenicillin) resistance (Apr or
Cbr) to bacteria that harbor pComb3 DNA. All other genes required for replication and
assembly of phage particles are lacking. Consequently, pComb3 needs a helper phage to
provide the phage proteins necessary for replication and packaging. The helper phage
VCSM13 which contains a gene coding for kanamycin resistance (Kmr) is used to
superinfect bacteria that has been transformed with pComb3 DNA. VCSM13 is a male-
specific phage i.e. host bacterial cells must contain an F factor that encodes the proteins
forming the pili which is necessary for infectivity of the male-specific phage (Cold
Springs Harbor Laboratory Course Manual, 1993).
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ANTIBODY REPERTOIRE CLONING BY PHAGE DISPLAY
(After Fischer, 1995)
Plasma cells
Lc RNA Hc RNA
pCommb3H
RT-PCR
Lc DNA Hc DNA
Restriction
Ligation into
pComb3H
Transformation into E. coli and 
superinfection with Helper phage
Multiple Biopanning and later, ELISA
Fab phages
∆gpIII
Transform E. coli
Soluble Fab
fragments
Fig. 1.0 Overview of the Phage display system with pComb3H. Amplified light and heavy chains
genes are cloned into a plasmid and used to transform bacteria. Superinfection with a helper phage
permits the production of phages  expressing antibodies whose genetic information are carried within
the phage coat. Desired antibodies are selected by successive rounds of biopanning, and subsequently
ELISA on the antigen of interest. Soluble Fabs are produced upon restriction of phage coat protein
gene III from the phage genome.
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Phage display however suffers from potential drawbacks. Non-productive aberrant
chains are often very well expressed and tend to be non-toxic to the bacterial host,
whereas cells expressing functional Fab-gene III fusions may have a growth
disadvantage and are selected against (Fischer et. al., 1999). The Fab-gene III fusion
protein can also cause vector instability, creating deletions in the antibody fusion genes
(Courtney et. al., 1995). The combinatorial construction of Fabs in the library makes it
difficult to discriminate original VH - VL pairings from ’de novo’ formed pairs, and
original pairing may be lost (Fischer, 1998). The panning process which by itself is very
difficult could lead to over-amplification of plastic binding clones which are inherently
present in the libraries.
pComb3H
lac Z
Light chain Heavy chain
STOP STOPgene IIIpel BRIBSSTOP  omp ARIBS
Sac I Xba I Xho I Spe I Nhe I Not I
Fig. 1.1 pComb3H is a modified derivative from the original pComb3 phagemid. The lac Z
promoter drives the synthesis of the light chain and Fd/gene III transcript. The two ribosome
binding sites initiate the translation of the two separate polypeptide chains; a complete light chain
(VL - CL), and the Fd fragment of a heavy chain (VH - CH1) fused to the carboxy-terminal
domain of the gene III protein. Random combination of light chain and Fd fragment PCR products
which have been independently amplified are cloned into the plasmid to generate a combinatorial
antibody library. The leader peptides omp A and pel B target both polypeptides to the bacterial
periplasm where the soluble light chain fragment and the membrane-bound Fd fragments associate
via a disulfide bond. The Sac I and Xba I restriction enzyme sites are provided for cloning light
chain fragments whilst Fd fragments are inserted at Xho I and Spe I restriction sites. Cleavage of
pComb3H by the restriction enzyme Spe I (A|CTAGT) and Nhe I (G|CTAGT) which have identical
cohesive ends that can be re-ligated results in the removal of the gene III product of M13
producing soluble Fabs. The wild type vector is provided in the form pComb3H-SS where the SS
designation is for stuffer fragments. The stuffer fragments have not been well characterized in
detail but they lack the restriction sites found in the vector. (After Rader and Barbas, 1997).
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Phage antibodies are either produced as scFv or Fab fragments in E. coli, devoid of the
Fc portion. For therapeutic use the Fc portion is required to yield the month-long half-
life typical of antibodies (Barbas, 1995). The immobilization of antigen in plastic wells
during panning results in masking or inaccessibilty of some epitopes on the antigen,
compromising the conformational integrity of the antigen.
1.3.4 Recombinant antibody gene expression in E. coli
The wealth of knowledge accumulated from E. coli genetics makes it an attractive
cloning vehicle for the expression of recombinant antibody fragments. Besides, growth
of E. coli is inexpensive, cell growth is fast, and DNA transformation as well as
transfection (infection) with phage is extremely efficient (Cold Spring Harbor
Laboratory Course Manual, 1993). A disadvantage with using E. coli is that a whole
antibody molecule including the Fc portion which is important for effector functions,
and glycosylation which influence the complete molecule cannot be expressed in E.
coli, since E. coli cannot glycosylate proteins (Verhoeyen and Windust, 1996).
1.4 SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology
involving multiple organs with diverse and variable clinical manifestations. The disease
is characterized by production of anti-nuclear antibodies, generation of circulating
immune complexes, activation of the complement system, initiating and causing
inflammation of the joints, kidney, brain, lung, skin, etc. The American
Rheumatological Association have established criteria to guide medical practioners in
diagnosing SLE cases (Table 1.1).
Any 4 of the 11 criteria is an indication of SLE. Patients with SLE produce
autoantibodies to self-components with antinuclear antibodies being prevalent. Among
these are autoantibodies to chromatin, the U1 and Sm small nuclear ribonucleoprotein
(snRNP) particles, the Ro/SSA and La/SSB RNP complexes (Kotzin, 1996). U1 is a
uridine-rich snRNA complexed with various polypeptides designated as 70-kD, and
proteins A - G. Anti-Ro/SSA and anti-La/SSB antibodies have been implicated to have
a direct pathogenic role in the development of some manifestations such as skin lesions
of subacute cutaneous lupus erythematosus and congenital heart failure (Tomer et. al.,
1993). Anti-Ro/SSA and anti-La/SSB antibodies in SLE are 17 - 63 % and 6 - 35 %
respectively. Other autoantibodies include anti-phospholipid antibodies (which
complexes to β2-glycoprotein 1) that are associated with thrombotic complications in
some patients. Another subset of autoantibodies in systemic lupus erythematosus are
directed to cell surface molecules. These immunopathological autoantibodies are
observed in diseases such as idiopathic thrombocytopenia (platelet destruction) and
14
hemolytic anemia (red blood cells destruction). Anti-dsDNA antibodies which are the
hallmark of systemic lupus erythematosus (Stollar, 1989) and which serves as a major
diagnostic marker for the disease appear to play a prominent role in the immune
complex glomerulonephritis.
Table 1.0 The 1982 revised criteria for SLE (Tan et. al., 1982).
Criterion Definition
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the
nasolabial folds
2. Discoid rash Erythematous-raised patches with adherent keratotic scaling and follicular
plugging; athropic scarring may occur in older lesions
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or
physician observation.
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a physician
5. Arthritis Nonerosive arthritis involving two or more peripheral joints, characterized by
tenderness, swelling, or effusion
6. Serositis a. Pleuritis - convincing history of pleuritic pain, or rub heard by physician, or
evidence of pleural effusion, or
b. Pericarditis - documented by electrocardiogram, rub, or evidence of
pericardial effusion
7. Renal disorder a. Persistent proteinuria greater than 0,5 g per day, or greater than 3+ if
quantitation is not performed, or
b. Cellular casts, red cell, hemoglobin, granular, tubular, or mixed.
8. Neurologic
    disorder
a. Seizures, in the absence of offending drugs or known metabolic
derangements, e.g. uremia, ketoacidosis, or electrolytic imbalance, or
b. Psychosis, in the absence of offending
9. Hematologic
    disorder
a. Hemolytic anemia with reticulocytosis, or
b. Leukopenia, less than 4 x 106/ml two or more occasions,
c. Lymphopenia, less than 1.5 x 106/ml,
d. Thrombocytopenia, less than 100 x 106/ml in the absence of offending drugs.
10. Immunologic
      disorder
a. Positive LE cell preparation, or
b. Anti-native DNA antibody in abnormal titer, or
c. Anti-Sm present, or
d. False-positive serologic test for syphilis known to be positive for at least 6
months and confirmed by negative Treponema specific test
11. Antinuclear
      antibody
An abnormal titer of ANA by IF or an equivalent assay at any point in time and
in the absence of drugs associated with drug-induced lupus
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Anti-dsDNA antibodies which rarely occurs in other conditions are virtually diagnostic
of SLE. The combination of high levels of anti-DNA antibodies with how levels of C3
is virtually 100 % diagnostic of SLE in patients who are suspected to have the disease
on clinical grounds. Most anti-dsDNA antibodies recognize the sugar phosphate
backbone of DNA, while others are base specific or bind to unique three-dimensional
structures on DNA. The pathological consequence of anti-DNA antibodies is their role
in kidney damage. Immune complexes of DNA-anti-DNA are deposited in the kidney
glomeruli, or sometimes they form in situ in the kidney. An alternate hypothesis have it
that anti-dsDNA antibodies are able to cross-react with glomerular structures that are
not DNA in origin (Kotzin, 1996). Local complement activation induces
glomerulonephritis with a detectable consumption of serum complement (Balow, 1991).
It is important however to note that the presence of high levels of abnormal serum anti-
dsDNA titer does not correlate with any particular manifestation of SLE except
nephritis. Thus, it is not possible to predict from serological results that a given patient
will develop renal disease, for example (Tomer et. al., 1993).
1.5 IDIOPATHIC THROMBOCYTOPENIC PURPURA
Platelets differentiate from megakaryocytes which are very large polyploid bone
marrow cells. Upon migration from the bone marrow space, one-third are sequestered in
the spleen, while the remaining two-thirds circulate for 7-10 days. The normal blood
platelet count varies between 150,000 - 450,000/µl and since only a small fraction are
consumed in the process of hemostasis, most platelets circulate until they become
senescent and are removed by phagocytic cells.
The normal function of platelets is their adherence and aggregation to cover damaged
areas. Thus when the endothelium is damaged, subendothelial layers come into direct
contact with the blood, and platelets adhere and aggregate to cover up the damaged
areas (Deckmyn and De Reys, 1995; Macchi et. al., 1997). In the subendothelium,
platelets bind directly through their collagen receptors (e.g. gpIa/IIa, gpVI), or
indirectly through the adhesion protein - von Willebrand factor (vWF), forming a bridge
between the subendothelium and the vWF receptor on the platelets. vWF binds to
platelets through contact with glycoprotein Ib (gpIb). The multimeric vWF interacts
with gpIb on other platelets resulting in agglutination. Aggregated platelets become
activated, produce and secrete or facilitate the production of additional platelet-
activating substances such as adenosine diphosphate (ADP), serotonin, thromboxane
A2, thrombin, and gpIIb/gpIIIa which help in the recruitment of additional platelets.
Platelet to platelet contact is maintained when gpIIb/IIIa on adjacent platelets are
bridged by fibrinogen during platelet aggregation. Deficiency of gpIIb/IIIa, or
antibodies interfering with their function, particularly antibodies blocking the final step
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of platelet aggregation i.e. inhibiting fibrinogen to bridge adjacent gpIIb/IIIa, have
profound effects in humans; it results in severe bleeding. Idiopathic thrombocytopenic
purpura (ITP) is an autoimmune disease caused by circulating antibodies that react with
target antigens (the glycoproteins gp IIb-IIIa, gp Ib-IX) on platelet membranes, with the
consequence that the platelets are recognized and eliminated by the host’s immune
system (Woods et. al., 1984; Kiefel et. al., 1991). The anti-glycoprotein antibodies
function as opsonins and accelerate platelet clearance by phagocytic cells. The resultant
thrombocytopenia (depletion of platelets) induces a purpura (hemorrhage discharge into
skin, mucous membranes, internal organs and other tissues) when the platelet count
reaches a critical level, usually < 30,000/µl (Karpatkin, 1997). Platelets interact with Fc
parts of antibodies via the FcγII receptor, cross-linking of which can lead to platelet
aggregation. Other mechanisms involve Fc independent platelet inactivation and
complement-mediated platelet activation. Autoantibodies in idiopathic
thrombocytopenic purpura (ITP) can occur in combination with another disease or not,
and can be accompanied by thrombocytopenia or without. Anti-platelet antibodies are
involved in hematological complications in patients with systemic lupus erythematosus
displaying circulating auto-antibodies to platelets, red blood cells, lymphocytes, and
nuclear and cytoplasmic cellular components.
Treatment of idiopathic thrombocytopenic purpura is directed towards the inactivation
or removal of a major site of platelet destruction and anti-platelet antibody production
namely, the spleen. Administration of corticosteroids prevents sequestration of
antibody-coated platelets by the spleen. There arises decreased Fc γ-receptor expression
on macrophages thus inhibiting phagocytosis of platelets. In addition, the amount of
platelet-associated IgG decreases, thus corticosteroids also impair antibody production
and/or binding to platelets. Splenectomy which is only done seldomly, removes the
potential site of destruction of damaged platelets as well as the source of anti-platelet
antibody production. Since a third of platelet mass is sequestered in the spleen,
splenectomy results in increased platelet count of about 30%. However, post-
splenectomy thrombosis is a benign self-limited condition that does not require specific
therapy. High dose IVIG (1 g/kg in 2 days) is given as emergency treatment in ITP
patients with platelet count below 10,000/µl. IVIG induces increased platelet counts and
the mechanism of action is believed to be via blockade of the reticuloendothelial system
and, the presence of anti-idiotype antibodies in the IVIG preparation (Bussell and
Hilgartner, 1986).
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1.6  INTRAVENOUS IMMUNOGLOBULINS (IVIG)
Intravenous immunoglobulins (IVIG) are pooled normal polyspecific immunoglobulin
G (IgG) obtained from serum of several thousand healthy donors. IVIG contains
primarily unmodified IgG which has functionally intact Fc-dependent effector functions
and only trace amounts of IgA, IgM, soluble CD4, CD8 and HLA molecules (Blasczyk
et. al., 1993). Since IVIG is prepared from large donor pools (typically more than
10,000), they represent a broad spectrum of antibodies reflecting the natural exposures
and immunizations of the adult populations from which the donors were drawn (Wolf
and Eibl, 1996). IVIG therapy is mostly used in patients suffering from primary
immunodeficiency syndromes. IVIG is also administered in anti-inflammatory diseases
and several autoimmune diseases such as idiopathic thrombocytopenia (Imbach et. al.,
1985) autoimmune hemolytic anemia, dermatomyositis, refractory systemic lupus
erythematosus, myasthenia gravis, Kawasaki disease (Fischer et. al., 1996; Wolf and
Eibl, 1996).
The proposed mechanism of action of IVIG in autoimmunity and systemic
inflammatory diseases include: the blockade of Fc-gamma (Fc-γ) receptors on
phagocytic cells, interference with activated complement, modulation of cytokine
production and release, modulation of T and B lymphocyte functions, suppression of
autoantibody production, and selection or shaping of immune repertoires (Mouthon et.
al., 1996). IVIG has been observed to block and saturate Fc-gamma receptors on cells
of the reticuloendothelial system namely, macrophages and monocytes, as well as
neutrophils, and T and B cells. Administration of IVIG to ITP patients resulted in
decreased clustering of IgG-coated thrombocytes (Kimberly et. al., 1984) and an
increased platelet count (Clarkson et. al., 1986). These observations are attributed to the
blockade of Fc-γ receptors-mediated clearance of autoantibody-coated thrombocytes.
IVIG has been shown in vivo to interfere with activated complement by binding to the
C3b and C4b components and diverting them from interacting with target cells during
complement activation (Basta et. al., 1991). Basta and Dalakas (1994) reasoned the
observed decrease in complement deposition in small vessels of dermatomyositis
patients treated with IVIG was most likely due to formation of complexes between
IVIG and activated complement components such as C3b. The anti-inflammatory
effects of IVIG in vivo have been observed in the way IVIG interferes with cytokine
production in B and T cells. In vitro studies on cultured monocytes have revealed that
IVIG behaves as an anti-inflammatory agent as it triggers the production and
extracellular release of interleukin-1 (IL-1) receptor antagonist (IL-1ra), a naturally
occurring inhibitor of IL-1 activity. IL-1 is a pro-inflammatory cytokine produced by
monocytes and macrophages in response to lipopolysaccharide (LPS), or Fc-γ receptor
cross-linking by surface-bound IgG, soluble polymeric IgG or IgG-containing immune
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complexes (Wolf and Eibl, 1996). In vivo administration of  IVIG to Kawasaki disease
patients led to a decreased production of IL-1 (Leung et. al., 1989) as well as in rabbits
injected with LPS mixed with IVIG (Arend et. al., 1991). It is believed the beneficial
effect of IVIG in modulating decreased amounts of pro-inflammatory monokines is that
it suppresses production of TNF-α and IL-1 by elevating intracellular levels of cyclic
adenosine 3’, 5’-monophosphate (cAMP) following its interaction with Fc-γ receptors on
monocytes (Shimozato et. al., 1991).
Some immunomodulatory effect of IVIG is due to its reactivity with functional
molecules on lymphocytes. IVIG reacts with CD5 and CD4 molecules on lymphocytes
(Hurez et. al., 1994; Vassilev et. al., 1993). CD5+ (B-1) subpopulation of B cells are
believed to be a predominant source of autoantibody producing cells (Casali and
Notkins, 1989), thus the presence of anti-CD5 antibodies in IVIG may be of potential
relevance for therapeutic modulation of autoimmunity. IVIG has also been shown to
react with the CD4 molecule on T and B cells (Lam et. al., 1993). Anti-CD4 antibodies
purified from IVIG have been found to inhibit in vitro infection of CD4+ T cells by
HIV-1 (Hurez et. al., 1994). IVIG contains antibodies capable of reacting with the V-
region of other antibodies (anti-idiotypic antibodies) and B cell antigen receptors. The
presence of anti-idiotypic antibodies in IVIG is demonstrated by specific retention of
autoantibodies on affinity columns of IVIG coupled to sepharose. These anti-idiotypic
antibodies in IVIG have the ability to inhibit the activity of autoantibodies or
downmodulate their production (Wolf and Eibl, 1996). IVIG also contains IgG fractions
against certain Vβ chains of the T cell receptor lineage (Marchalonis et. al., 1992) and
have the capability to regulate the function of pathogenic autoreactive T cells. The
suppressive effects of IVIG have been observed in its ability to inhibit the proliferation
of in vitro activated B and T lymphocytes (Wolf and Eibl, 1996). IVIG was observed to
have suppressed the production of IgM by EBV-transformed B lymphoblastoid cells
(Kondo et. al., 1994), and also inhibited B cells stimulated by pokeweed mitogen from
producing antibodies (Kondo et. al., 1991). In addition, the presence of other
immunologically active proteins (other than immunoglobulins) in IVIG preparations
may contribute to its immunomodulatory effects. These include HLA class I and II
antigens and soluble CD4 and CD8 molecules. These molecules are thought to play a
role in cell-cell interactions during immune response and may contribute to
immunomodulation of IVIG (Wolf and Eibl, 1996). Other antibody activities found in
IVIG preparations (due to its large antibody repertoire) which could influence its
mechanism of action include antibodies to alloantigens such as blood group antigens
(Gordon et. al., 1980), HLA antigens, and rheumatoid-factor-like isotype specific
antibodies (Quinti et. al., 1987).
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1.7 THE IDIOTYPIC-ANTIIDIOTYPIC NETWORK IN AUTOIMMUNITY
Idiotypic networks are thought to regulate humoral and possibly cell-mediated
immunity. First proposed by Jerne (1974), the theory hypothesizes that the variable
regions of antibodies or B cell receptors (idiotypes) can induce the formation of a
second set of antibodies or B cell receptors (anti-idiotypes) with specificities against the
first set. Some of the anti-idiotypic antibodies may recognize the antigen-combining site
or paratope on the primary antibody in which case they appear as the ’internal image’ of
the original inducing epitope on the antigen. These antibodies are termed Ab2β. Other
anti-idiotypes may recognize epitopes lying outside the paratope on Ab1 (the primary
antibody). These subsets of anti-idiotypes are referred to as Ab2α. The network theory
predicts that the idiotypes on Ab2 antibodies can also elicit Ab3 or anti-antiidiotopic
antibodies whose idiotopes mimic that of Ab1, thereby limiting the network as
decreasing levels of antibody are produced in each round of activation (Kuby, 1997).
The network theory further predicts that within an individual, the interconnection
between complementary idiotypes and anti-idiotypic structures on antibody molecules,
as well as  B and T lymphocytes leads to an immunoequilibria state (Potter and Capra,
1995). This state could potentially be disrupted through mimicry of self-antigen by
auto-antiidiotypic antibody resulting in a regulatory breakdown, the outcome of which
could be autoimmune disease. Theories of the idiotypic network controlling
autoimmunity are about observations that certain anti-idiotype antibodies administered
perinatally can lead to prolonged inhibition of the corresponding (autoimmune)
idiotypes later in life, presumably by blocking immunoglobulin receptors on immature
B cells which are then deleted (Kearney and Vakil, 1986). However, certain anti-
idiotype antibodies given neonatally enhance idiotype-positive B cell responses even in
the absence of T cell help (Leffel, 1997).
 1. 8 AIMS OF THIS STUDY
  The objective of this study is the use of the phage display technology to investigate:
1. the molecular analysis of Fabs bound by IVIG in a patient with SLE,
2. compare these Fabs with similar ones from patients with AITP cloned in our
laboratory,
3. understand the mechanism(s) by which IVIG interact with Fabs.
20
2. 0 MATERIALS AND METHODS
Unless otherwise credited with the manufacturers of reagents and equipment, commonly
used buffers including TE, TAE, PBS, TBS, and bacterial culture media like LB, SB,
and SOC, as well as LB plates with the appropriate antibiotics were all prepared as
recommended by Sambrook et. al., 1989.
2. 1 PATIENT
A girl (SH), aged 8 years and 5 months was transferred to our hospital because of acute
myocarditis with clinical signs of cardiac failure. Two days earlier, upon her admission
to another hospital, she had presented with ascites, peripheral and pulmonary edema,
and a weight gain of 4 kg due to progressive heart failure. Also present were an elevated
antistpreptolysin O titer of 800 IU/ml (which increased to maximum of 1,170 IU/ml),
erythema marginatum, fever, hematuria, and proteinuria. Since she met 2 of the major
Jones criteria (cardiac failure most likely due to preceding carditis and erythema
marginatum) and at least 1 of the minor Jones criteria - fever (Jones 1944), and since
she had no other specific symptoms, she was treated for rheumatic fever. Specific
virologic examinations to rule out viral carditis did not provide significant evidence of
an acute infection. The patient was seropositive for several antinuclear antibodies
(ANA) including, anti-Ro/SSA, anti-LA/SSB, anti-Sm, antihistone, and anti-Scl 70
(Topoisomerase I), anti-ribosome. Anti-dsDNA antibodies were positive only once by
ELISA at a borderline level of 6.3 IU/ml (cutoff 5.97 IU/ml). Repetitive DNA ELISAs
and the immunofluorescence test for Crithidia luciliae were always negative. After
undergoing IVIG, high-dose penicillin and aspirin therapy, our patient was discharged
for further outpatient care. Her antistreptolyson titer had dropped to 507 IU/ml during
therapy. Several days prior to a scheduled admission for heart catheterization (since
cardiac function was still borderline), the patient had to be readmitted for fever,
headache and vomiting. Upon examination, stomatitis, macrohematuria, a sore throat,
and cervical lymphadenopathy were present. Heart biopsy upon catheterization did not
show signs of viral infection or vasculitis. At this point, however, renal biopsy showed
mesangial lupus nephritis (World Health Organization grade II). In the course of
clinical follow up, ANA remained positive (Osei et. al., 2000).
2. 2 ISOLATION OF LYMPHOCYTES FROM PERIPHERAL BLOOD
LYMPHOCYTES
Isolation of lymphocytes from peripheral blood lymphocytes (PBLs) was carried out by
using Ficoll-Paque reagent (Pharmacia, Freiburg, Germany). Ficoll-Paque, a sodium
diatrizoate solution, is a low viscousity medium which offers rapid isolation and high
quality lymphocytes. Diluted anticoagulant-treated blood is carefully layered on the
Ficoll-Paque solution and centrifuged  for a short period of time. Differential migration
21
of the components of blood during centrifugation results in the formation of layers
containing different cell types; erythrocytes and granulocytes sediment to the bottom,
and lower density lymphocytes are sandwiched between an upper layer plasma and the
Ficoll-Paque reagent. The lymphocytes are then recovered from the interface and
washed with PBS to remove platelets, Ficoll-Paque and plasma that might be present.
The upper layer plasma which is essentially free of cells may be saved for future use.
20 ml peripheral blood was obtained from the systemic erythematosus and rheumatic
fever patient for phage display library construction. 90 ml Ficoll-Paque was pipetted
into two 50 ml centrifuge tubes and 10 ml vol/vol PBS:blood was carefully and slowly
layered on top of each with the tube held at a slanting position of about 50 degrees. The
mixture was centrifuged for 30 minutes at 1,500 rpm in a Beckman GS-6 Centrifuge
(Beckman Instruments Inc, Palo Alto, Ca, USA) with the brakes turned off. Using a
Pasteur pipette, the upper layer plasma was carefully aspirated, aliquoted into 1.5 ml
microfuge tubes and stored at -80 oC. The lymphocytes were aspirated, pooled into new
50 ml tube, topped to 20 ml with PBS and homogenized by gentle swirling, and ca. 30
µl was saved for lymphocyte count on a hemocytometer (HBG, Germany) using
Jenamed2 flourescence microscope (Carl Zeiss Jena,  Germany). The lymphocytes were
centrifuged for 10 minutes at 1,200 rpm with the brakes at ’low’ position, and the pellet
was used for total RNA isolation.
2. 3 RNA ISOLATION FROM LYMPHOCYTES
Isolation of total RNA from lymphocytes was carried out by using TRI reagent
(MOLECULAR RESEARCH CENTER, INC, Cincinnati, OH, USA) according to the
manufacturer´s protocol. TRI reagent contains phenol and guanidine thiocynate in a
monophase solution. The RNA isolation steps basically include homogenizing or lysing
the sample in TRI reagent, phase seperation  from the aqueous phase by adding
chloroform and centrifuging, RNA precipitation  from the aqueous phase by additon of
isopropanol, RNA wash using ethanol, and RNA pellet resuspended in appropriate
buffer.
The lymphocytes (ca. 106-107 cells/ml) were homogenized in 1 ml TRI reagent and
incubated at room temperature for 5 minutes. 200 µl chloroform (Merck GmbH,
Darmstadt, Germany) was added, vigorously shaken for 15 seconds and incubated at
room temperature for a further15 minutes, and centrifuged at 12,000 xg (ca. 11,500
rpm) for 15 minutes at 4 oC. The aqueous phase was carefully pipetted into a new
microfuge tube, mixed with 500 µl isopropanol (Merck, Germany), incubated at room
temperature for 10 minutes, and centrifuged at 12,000 xg for 10 minutes at 4 oC. The
pellet was washed with 1 ml of 75% ethanol (Merck, Germany), centrifuged as above,
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air-dried briefly for about 5 minutes and resuspended in 50 µl TE buffer. 10 µl of the
RNA was analysed on 1% agarose (Gibco BRL, USA) gel electrophoresed at 200 V for
15 minutes. The rest of the RNA was stored at -80 oC for synthesis of cDNA.
2. 4 SYNTHESIS OF Fd, λ AND κ cDNA BY REVERSE TRANSCRIPTION
Total RNA was used for the synthesis of first strand cDNA using 3’ primers that were
subsequently  used in the PCR. The 3’ primers specifically associate to the 3’ end of the
light chain (CL) constant region or the CH1/hinge (Heavy chain) allowing for
incorporation of the interchain cystein codon of each chain in the product (Persson et.
al. 1991; Kang et. al., 1991b).
10 µl of total RNA was added to 2 µl of either heavy (Fd; VH + CL1), or light chain
(κ and λ) 3’ constant region primer in a 1.5 ml microfuge tube, 8 ml of sterile water was
added, and incubated at 70 oC for 10 minutes, chilled for 5 minutes on ice and
centrifuged for 5 seconds. 7 µl sterilized water, 10 µl 5x reverse transcriptase buffer
(Gibco BRL, Life Technologies, USA), 5 µl DTT (Gibco BRL, USA), 2 µl RNAase
Inhibitor (Promega, Madison, WI, USA), 3 µl dNTP-mix (Promega, USA), were added,
mixed and incubated at 42 oC for 2 minutes, and 3 µl Superscript reverse transcriptase
(Gibco BRL, USA), was added and incubated at 42 oC for 50 minutes. The reaction was
centrifuged for about 10 seconds, incubated at 70 oC for 15 minutes, briefly centrifuged
for about 10 seconds and incubated for 10 minutes on ice. 1 µl RNAase H (Promega,
USA) was added, and incubated at 37 oC for 20 minutes. The resulting cDNA was
shortly centrifuged and stored at -20 oC for PCR.
2. 5 RT-PCR AMPLIFICATION OF Fd, λ, AND κ CHAINS
Each PCR was run in a 0.5 ml microfuge tube in a total volume of 100 µl and contained
75.2 µl sterile water, 10 µl of 10x PCR buffer (without Mg2+-ions; Promega, USA), 5 µl
(1.25 mM) MgCl2 (Promega, USA), 0.8 µl dNTP-mix (final concentration 200 µM), 3
µl of either 3’ constant region primer namely, cG1z, cK1d, cL2, 3 µl of the appropriate
5’ variable region primer, 1 µl (5 Units) Taq DNA polymerase (Promega, USA), a drop
of mineral oil (Sigma Chemical Co., St. Louis, MO, USA), and 2 µl of the
corresponding 3’ constant region primer cDNA (template). For either positive or
negative control reactions, the following 5’ variable region primers were used: conGa
(VH chains), conKa (kappa chains) and conL1 (lambda chains), [Table 1,1]. In negative
control reactions however, no cDNA were added, rather water was added. Finally, the
reaction was centrifuged for about 30 seconds at 12,000 rpm and thermocycling was
carried out in a HYBAID Omnigene DNA Thermocycler (MWG-BioTech GmbH,
Germany), using the following reaction conditions; initial denaturation: x1 (94 oC) for 3
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minutes, cycling: x40 with primer annealing - 52 oC for 1 minute, extension - 74 oC for
1 minute, denaturation - 93 oC for 30 seconds, and final extention - 74 oC for 10
minutes. At the end of the thermocycling, 10 µl of the PCR reaction was run on a 2%
agarose gel using ΦX 174/Hae III marker (Gibco BRL, Life Technologies, USA). A
band of ca. 680 bp for VH and LH fragments, 330 bp for the positive controls, and no
amplication product(s) in the negative controls were indicative of a successful PCR.
2. 5. 1 Purification and Quantification of PCR products
PCR DNA was eluted and purified from agarose gel using S & S Biotrap (Schleicher &
Schuell GmbH, Dassel, Germany). The Biotrap is an electro-seperation system for
elution and purification of charged macromolecules e.g. proteins as well as nucleic acid
fragments from 14 to 150,000 base pairs without losses due to denaturation.
Except the PCR product controls using conGa (Fd), and conKa/conL1 (light chain) that
were discarded, the rest of the PCR products were pooled as follows; all Fd products
were combined together and, all light chain products (κ and λ) also combined together.
Each was extracted with 1:1 vol./vol. of Phenol:Chloroform (Roti-Phenol, Carl Roth,
Germany). The PCR DNA was run on 2% agarose gel at 150 V for 1-1/2 hours. The
heavy and light chain PCR products were excised out of the agarose gel and
electroeluted from the gel slice at 200 V for 1-1/2 hours using the S & S Biotrap,
extracted with 1:1 vol./vol. Phenol:chloroform, and each resuspended in 50 µl TE
buffer. 1 µl of the DNA was analysed on a 2% agarose gel and the concentration of the
light and heavy chain PCR products were determined to be 0.491 µg/µl and 0.598 µg/µl
respectively.
2. 5. 2 Restriction of PCR products
Preparation of antibody light and heavy chain inserts for cloning was carried out by
enzymatic double restriction using Sac I (40 U/µl) and Xba I (40 U/µl) which utilize
buffer A for light chain DNA and, Xho I (40 U/µl) and Spe I (40 U/µl) which utilize
buffer H for heavy chain DNA (Bohringer Mannheim GmbH, Germany).
10 µg light chain PCR DNA (0.491 µg/µl) was restricted using 1.5x excess units of
the light chain restriction enzymes i.e. 57 U Sac I/µg DNA and 112.5 U Xba I/µg DNA.
The reaction was incubated at 37 oC for 3h, ethanol precipitated, electroeluted as above,
resuspended in TE buffer, and quantitated. Similarly, 10 µg heavy chain PCR DNA
(0.598 µg/µl) was restricted using 1.5x excess units of the heavy chain restriction
enzymes i.e.109.5 U Xho I/µg DNA and 25.8 U Spe I/µg DNA, at 37 oC for 3h, ethanol
precipitated, electroeluted, resuspended in TE buffer, and the amount measured.
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PCR PRIMERS
Table 1.1 Human variable and constant region PCR primers used for phage antibody library
construction (Kang et. al., 1991b).
Human Heavy Chain Variable Domain 5’ Primers
VH1a 5’ - CAG GTG CAG CTC GAG CAG TCT GGG - 3’ (24 mer)
VH1f 5’ - CAG GTG CAG CTG CTC GAG TCT GGG - 3’ (24 mer)
VH2f 5’ - CAG GTG CAG CTA CTC GAG TCG GG  - 3’ (23 mer)
VH3a 5’ - GAG GTG CAG CTC GAG GAG TCT GGG - 3’ (24 mer)
VH3f 5’ - GAG GTG CAG CTG CTC GAG TCT GGG - 3’ (24 mer)
VH4f 5’ - CAG GTG CAG CTG CTC GAG TCG GG  - 3’ (23 mer)
VH4g 5’ - CAG GTG CAG CTA CTC GAG TGG GG  - 3’ (23 mer)
VH6a 5’ - CAG GTA CAG CTC GAG CAG TCA GG  - 3’  (23 mer)
Human Heavy Chain constant domain 3’ Primer
IgG1 CG1z 5’- GCA TGT ACT AGT TTT GTC ACA AGA TTT
GGG  - 3’
(30
mer)
Human Heavy Chain constant domain control 5’ Primers
IgG1 ConGa 5’ - TCC ACC AAG GGC CCA TCG  - 3’ (18
mer)
Human Light Chain Primers
Kappa chain variable domain 5’ primers
VK1a 5’ - GAC ATC GAG CTC ACC CAG TCT CCA -3’ (24 mer)
VK1s 5’ - GAC ATC GAG CTC ACC CAG TCT CC -3’ (23 mer)
VK2a 5’ - GAT ATT GAG CTC ACT CAG TCT CCA -3’ (24 mer)
VK3a 5’ - GAA ATT GAG CTC ACG CAG TCT CCA -3’ (24 mer)
VK3b 5’ - GAA ATT GAG CTC AC(G/A) CAG TCT CCA -3’ (24 mer)
Kappa chain constant domain 3’ primers
CK1d 5’ - GCG CCG TCT AGA ATT AAC ACT CTC CCC TGT TGA
AGC TCT TTG TGA CGG GCG AAC TCA G -3’
(57 mer)
Kappa chain constant domain control 5’ primers
CONKa 5’ - ACT GTG GCT GCA CCA TCT G -3’ (19 mer)
Lambda chain variable domain 5’ primers
VL1 5’ - AAT TTT GAG CTC ACT CAG CCC CAC -3’ (24 mer)
VL2 5’ - TCT GCC GAG CTC CAG CCT GCC TCC GTG -3’ (27 mer)
VL3 5’ - TCT GTG GAG CTC CAG CCG CCC TCA GTG -3’ (27 mer)
VL4 5’ - TCT GAA GAG CTC CAG GAC CCT GTT GTG TCT GTG -
3’
(30 mer)
VL5 5’ - CAG TCT GAG CTC ACG CAG CCG CCC -3’ (24 mer)
VL6 5’ - CAG ACT GAG CTC ACT CAG GAG CCC -3’ (24 mer)
VL7 5’ - CAG GTT GAG CTC ACT CAA CCG CCC -3’ (24 mer)
VL8 5’ - CAG GCT GAG CTC ACT CAG CCG TCT TCC -3’ (27 mer)
Lambda chain constant domain 3’ primers
CL2 5’ - CG CCG TCT AGA ATT ATG AAC ATT CTG TAG G -3’ (30 mer)
Lambda chain constant domain control 5’ primers
CONL1 5’ - AAG GCT GCC CCC ACG GTC ACT CTG -3’ (24 mer)
Underlined nucleotides represent primer-encoded restriction sites
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2. 6 PREPARATION OF E. coli STRAIN XL1-Blue FOR CLONING
The preparation of bacterial cells for high efficiency transformation involves growing
the bacteria to early-to-midlog phase. This offers a period of greatest competence where
the cells are still growing rapidly at densities (and volumes) high enough to recover
very large number of cells. The cells are harvested by chilling and centrifuging, and for
electroporation, washed several times with water and resuspended in 10% Glycerol in
deionised water to reduce the ionic strength of the final cell suspension (Gene Pulser
Controller, Operating Instructions and Applications Guide, BIO RAD, USA).
Increasing cell concentration increases yield of transformants, therefore cells are
resuspended to very high concentration, aliqouted and stored at -80 oC. The E. coli
strain XL1-Blue (Stratagene, U.S.A) has the following genotype:
recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac-
F’ (proAB+, lacIq, ZdelM15, Tn10).
XL1-Blue allows high efficiency transformation, up to 109 colonies per µg of pUC
DNA when using electroporation (Cold Spring Harbor Laboratory Course Manual,
1993). XL1-Blue is recombination-deficient (rec A1) which is necessary to maintain
stability of plasmids propagated in this strain. In addition, transposon 10 (Tn 10) which
harbors the gene coding for resistance towards the antibiotic tetracycline (tetr) has been
intergrated into the F’ factor. This ensures the expression of the F’ factor in media
containing tetracycline and maintains the ability of the bacteria to act as a host for male-
specific phages such as M13.
300 µl glycerol stock of E. coli strain XL1-blue (Stratagene Cloning Systems, La Jolla,
Ca., USA) was resuspended in 5 ml SB medium supplemented with 20 µl of 10 mg/ml
tetracycline (Merck, Germany) and incubated overnight with shaking (300 rpm) at 37
oC. 3 ml of the overnight culture was transferred into a 37 oC pre-warmed 300 ml SB
medium containing 600 µl tetracycline (10 mg/ml) and incubated as above until mid-log
phase (for ca. 3 h), when the OD600 = 0.8 - 1.0. The culture was incubated on ice for 20
minutes and divided into 6 pre-chilled 50 ml tubes, and centrifuged at 4,800 rpm (3,838
xg) for 10 minutes at 4 oC. The supernatant was discarded and the pellet resuspended in
10 ml ice-cold water, topped to 50 ml and re-centrifuged as above. The pellet was
resuspended in 25 ml ice-cold water and centrifuged again, and was resuspended in 1 ml
10% glycerol (Carl Roth, Germany). The cells were pooled into two tubes and
centrifuged as above, pooled and resuspended in 3 ml of 10% glycerol and aliqouted at
200 µl into 1.5 ml microfuge tubes directly onto dry ice and stored at -80 oC. To test
whether the cells were viable and devoid of contamination, 50 µl were plated on
carbenicillin (Merck, Germany) [100 µg/ml LB medium], kanamycin (Sigma, USA) [70
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µg/ml LB medium], and tetracycline (10 µg/ml LB medium) plates, and incubated
overnight at 37 oC. Inspection of the plates next morning showed that there were no
growth on the carbenicillin and kanamycin plates indicating that the XL1-blue strain
had not acquired resistance to these two markers whilst there were clones on the
tetracycline plates showing that the cells were viable. 1 µg wildtype phagemid,
pComb3HSS (Dr. Barbas, Scripps Research Institute, La Jolla, USA) was
electroporated into 200 µl of the cells to determine transformation efficiency of the
cells. This was determined to be 3.2 x 107 colonies/µg DNA.
2. 7 PREPARTION OF pComb3H VECTOR
2. 7. 1 Transformation of E. coli strain XL1-blue by High Voltage Electroporation
(Electrotransformation).
Transformation of bacteria by high voltage electroporation  is a convenient and reliable
way to achieve success in cloning. Frozen glycerol stock of bacteria  are thawed on ice
and used for transformation. Electroporation is carried out in a special high voltage
mini-electrode and chilled cuvettes. An optimal balance between the strength of the
electrical field, the length of the electrical pulse and the concentration of DNA results in
higher transformation efficiencies (Sambrook et. al., 1989).
1 µg of pComb3HSS DNA resuspended in 10 µl sterile deionised water was mixed with
200 µl thawed glycerol stock of E. coli strain XL1-blue cells and transferred into a
chilled 0.2 cm gap cuvette (Bio-Rad, USA), and pulsed at 2.5 kV, 25 µFD and 200
ohms for 4.5 seconds at a field strength of 12.5 kV/cm in a Gene Pulser (Bio-Rad,
USA). The electrotransformed cells were rapidly flushed with 3 ml SOC medium into a
10 ml tube and incubated at 37 oC for 1h, shaking (200 rpm), in a G 24 Incubator shaker
(New Brunswick Scientific Co. Inc., Edison, NJ, USA). The culture was transferred into
a 50 ml tube containing pre-warmed (37 oC) 10 ml SB medium supplemented with 2.6
µl carbenicillin,100 µl of 1M MgCl2 (Merck, Germany), and incubated as above. Prior
to the incubation, about 80 µl was saved for determining the efficiency of the
transformation by plating 50 µl, 1.0 µl, and 0.1 µl on LB plates containing 100 µg/ml
carbenicillin. The culture was transferred into a 1l conical flask containing 100 ml SB
medium supplemented with 56.0 µl of 100 µg/ml carbenicillin, 1 ml of 1M MgCl2 and
incubated overnight as above. The plasmid DNA was extracted with the QIAGEN MIDI
Plasmid kit the next day.
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2. 7. 2  pComb3HSS: QIAGEN MIDI plasmid purification
pComb3HSS DNA was purified using the QIAGEN MIDI plasmid purification kit
according to the manufacturers instructions. The QIAGEN plasmid kit is an alkaline
lysis based purification protocoll. It allows the purification of ultrapure  plasmid DNA
(yield ca. 100 µg DNA) without the use of phenol, chloroform, or cesium chloride
(QIAGEN Plasmid Purification Handbook). Essentially, the protocol involves lysis of
bacterial cells under alkaline conditions and after centrifugation, the lysate is applied
under defined salt conditions to a pre-equilibrated QIAGEN resin tip. The resin ensures
that only plasmid DNA is bound while degraded RNA, cellular proteins, and
metabolites are washed down the column under gravity. A high salt buffer efficiently
elutes plasmid DNA from the resin and the DNA is desalted and precipitated by
isopropanol. Finally, it is washed in 70% ethanol, dried briefly and resuspended in an
appropriate buffer.
The overnight pComb3HSS electrotransformed culture was divided 50 ml each into two
50 ml centrifuge tubes and centrifuged at 3,000 rpm (1,500 xg), for 20 minutes at 4 oC,
Beckmann GS-15R centrifuge. One pellet was used for purification of the wildtype
plasmid using the Qiagen Plasmid purification kit. 1 µg of the plasmid DNA was
analysed on 1% agarose gel with 1 kb DNA ladder (Gibco BRL, USA) as a marker.
2. 8 PREPARATION OF LIGHT CHAIN VECTOR FOR CLONING
The pComb3H-SS1 vector contains a light chain stuffer sequence of about 1,200 bp and
a heavy chain stuffer of 300 bp
10 µg pComb3H-SS DNA was restricted with Sac I and Xba I (6.25 U/µg and 12.5
U/µg respectively) at 37 oC, ethanol precipitated, run on 0.7% low melting agarose
(Sigma, USA) at 90 V, for 1 h and both vector DNA and light chain stuffer fragments
excised out, and electroeluted (seperately) in an S & S Biotrap. The DNA was ethanol
precipitated, resuspended in TE buffer, the amount measured and stored at -20 oC.
2. 9 TEST LIGATION-LIGHT CHAIN INSERT
Important parameters to consider during ligation of an insert (foreign DNA) to a vector
include an optimal ratio of insert to vector and the concentration of each DNA in the
reaction mixture (Sambrook et. al., 1989). To monitor the efficiency of ligation, it is
invaluable to carry out test ligations which should include the optimal ratio of cut vector
DNA to insert, the cut vector with ligase but without insert, and the cut vector DNA
                                                          
1
 pComb3H-SS: wild type plasmid
  pComb3H-S: light chain vector (with the light chain stuffer fragment excised out)
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only without neither insert nor ligase. These serve as a useful guide for the subsequent
ligation.
The light chain insert test ligation was as follows:
a.  43.2 ng pComb3H-S vector + 12.1 ng light chain insert + ligase
b.  86.4 ng pComb3H-S vector + 12.1 ng light chain insert + ligase
c.  86.4 ng pComb3H-S vector + ligase (no insert)
d.  86.4 ng pComb3H-S vector (no insert, no ligase)
Each reaction was carried out in a total volume of 5 µl, incubated at 16 oC overnight,
electroporated into 200 µl of E. coli strain XL1-blue, and titrated overnight as above.
Phenol/chloroform prepartion of (total) DNA and restriction enzyme analysis using the
light chain enzymes Sac I and Xba I for each test ligation was carried out to determine
which of the test ligations was (more) successful.
2. 9. 1 Light Chain Library construction: ligation of Light Chain insert to Light
Chain vector
2.2 µg pComb3H-S DNA was ligated to 0.605 µg light chain DNA overnight at 16 oC
i.e. 50x the concentrations of both light chain vector and insert from test ligation (a)
above, was used in the construction of the light chain library. 50 µl, 1.0 µl, and 0.1 µl of
the library were plated on carbenicillin plates (100 µg/ml LB medium). The light chain
library total DNA was extracted by using the QIAGEN Midi Plasmid preparation kit.
2. 9. 2 Light Chain Library: Single clones minipreps culture
Single clones from the carbenicillin plates were cultured overnight in SB medium
supplemented with 100 µg/ml carbenicillin. Minipreps were prepared by
phenol/chloroform extraction and the DNA analysed on agarose gel by light chain
restriction enzymes to determine the percentage of clones that had the light chain
fragment (insert).
2. 10 THE COMPLETE FAB LIBRARY CONSTRUCTION
A series of background test ligations, and restriction enzyme analyses of the ligations,
revealed that a 3:1 vector to insert molar ratio gave a higher percentage of desired
clones with about 70% having both the light and heavy chain inserts and this was used
during the actual ligation of the heavy chain insert to the heavy chain vector.
4.95 µg heavy chain vector DNA and 1.65 µg heavy chain insert were ligated overnight,
ethanol precipitated the next day, resuspended in 10 µl water and electroporated into
XL1-blue cells. The cells were grown at 37 oC for 1h with shaking and, transferred into
a prewarmed (37 oC) 10 ml SB medium containing 2.6 µl carbenicillin (low
concentration), and 100 µl 1M MgCl2. 50 µl, 1.0 µl, and 0.1 µl were titrated on
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carbenicillin LB plates, and the rest incubated for 1h as above. The culture was
transferred into a 37 oC prewarmed 100 ml SB medium supplemented with 56 µl
carbenicillin (high concentration) and 1 ml 1M MgCl2 and incubated for 1 h as above.
200 µl (7.0 x 1011 t.u/ml) of VCSM13 helper phage (Stratagene, Ca., USA) was added
to the culture and incubated for 2 h as above. 160 µl kanamycin was added to the
culture and incubated under the same conditions as above, overnight.
2. 11 PREPARATION OF THE NAIVE SURFACE DISPLAYED FAB PHAGES
The overnight culture was divided into two 50 ml tubes and centrifuged at 3,000 rpm
(ca. 1,500 xg) for 20 minutes at 20 oC in a Beckmann GS-15R centrifuge. The
supernatant was transferred into a GSA rotor flask and 4 g (4% w/v) PEG-8000 (Sigma,
USA) and 3 g (3% w/v) NaCl (Merck, Germany) was added and incubated on ice for 20
minutes. The bacterial pellet containing the unselected (total) library DNA was saved
for DNA isolation using the QIAGEN DNA Preparation kit. The PEG precipitated
phage suspension was centrifuged at 8,600 rpm for 20 minutes at 4 oC (in a Sorvall RC
5B Plus centrifuge using a GSA rotor). The supernatant was discarded and the pellet
was resuspended in 2 ml of 1% Casein (Sigma)/TBS (supplemented with 0.02% NaN3
[Merck, Germany]), and divided 1 ml each into two 1.5 ml microfuge tubes and
centrifuged for 5 minutes at 12,500. The two Fab phage suspensions (supernatants)
were stored at 4 oC (for biopanning), and -20 oC (for long term storage) whilst the
pellets were discarded.
2. 12 BIOPANNING
2. 12. 1 Coating of antigens
Maxisorp immunotubes (Nunc,Wiesbaden, Germany) were coated with 9 µg (300 µl)
IVIG (30 mg/ml) preparation (Sandoglobin, Sandoz, Basel, Switzerland) and stored at 4
oC.
2. 12. 2 Day 1
2. 12. 2. 1 Bacterial culture
200 µl glycerol stock of E. coli strain XL1-blue was thawed on ice and resuspended in
10 ml SB medium supplemented with 20 µl tetracyclin (10 µg/ml, and incubated at 37
oC for about 1 h (until mid-log phase, Absorbance at OD600nm = 0.8 - 1.2) with shaking.
2. 12. 2. 2 Panning methodology
Antigen-coated immunotube number 1 was washed 3x with wash buffer (0.2%
PBS/Casein-0.05% Tween 20 (Fluka, Switzerland) and once with PBS, blocked
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completely with blocking buffer (1% Casein/PBS) and incubated at 37 oC for 1 h. The
blocked tube was washed 2x with wash buffer and once with PBS, and 300 µl of the
Fab phage suspension was added and incubated at 37 oC for 2 h inside a humidified
chamber.
Using a Pasteur pipette, the Fab phage suspension were pipetted from the tube and
unbound phages washed off as follows: Panning 1; 1 ml wash buffer was pipetted into
the tube, and allowed to stand for 10 minutes at room temperature and aspirated. This
was repeated again and then rinsed with PBS. During subsequent panning rounds
however, the wash buffer was allowed to stand for 2 minutes (repeated 10x) and finally
rinsed once with PBS. 300 µl elution buffer [0.1M HCl (Merck)/glycine (Sigma), pH
2.2] was added to the tube, vigorously pipetted up and down, and incubated 10 minutes
at room temperature. The eluted phages were collected from the tube, and neutralized
with 60 µl neutralization buffer containing 2M Tris (Carl Roth, Germany)/HCl pH 9.0,
and used to infect 3 ml of E. coli strain XL1-blue culture (from above) and incubated at
37 oC for 20 minutes in a shaking incubator.
50 µl of the bacterial culture was plated on carbenicillin and tetracyclin plates and
incubated at 37 oC overnight as a control to ascertain that no phagemid and helper
phage contaminations had taken place in the bacterial hosts. The transformed 3 ml E.
coli was added to a 37 oC pre-warmed 10 ml SB medium supplemented with 2.6 µl
carbenicillin and 100 µl of 1M MgCl2, and briefly vortexed. 60 µl was saved for output
titration of the Fab phage (by plating 50 µl, 1.0 µl, and 0.1 µl on carbenicillin plates)
with the rest of the culture incubated further at 37 oC for 1 h, with shaking. Similarly for
input Fab phage titration, 10 µl of 10-7, 10-8, and 10-9 c.f.u/ml serial dilutions of the
infecting (PEG-precipitated) phage suspension were incubated with 50 µl of the
bacterial culture at 37 oC for 20 minutes and were plated on carbenicillin plates for Fab
phage input titration. The transformed 13 ml culture was added to a 37 oC-prewarmed
100 ml SB medium supplemented with 56 µl carbenicillin and 1 ml of 1M MgCl2, and
incubated at 37oC for 1 h, with shaking, and 200 µl (7.0 x 1011 t.u/ml) VCSM13 helper
phage was added, and incubated at for 2h as above. 160 µl kanamycin (70 µg/ml) was
added to the culture and grown overnight as above.
2. 12. 3 DAY 2 (and other subsequent rounds of panning)
Preparation of surface-displayed Fabs for the next round of panning was done exactly as
under section 2.10, above. For subsequent panning rounds, 300 µl of the PEG
precipitated Fab Phage suspension (from the previous panning) was incubated with the
coated antigen in the  immunotubes, washed, eluted, neutralized and used to re-infect
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freshly grown bacteria (as in Panning 1), and the panning steps continued as above.
Total library DNA was isolated from the bacterial pellet from the last round of panning
for further analysis, unlike the earlier panning rounds when the bacterial pellet was
discarded (during PEG/NaCl precipitation of the phages).
At the end of the last round of panning, single clones growing on carbenicillin plates
were cultured in 48-well plates containing 300 µl SB supplemented with carbenicillin
and 10 mM MgCl2 for 5 - 6 h at 37 oC with shaking. VCSM13 helper phages were
added and grown further for 1 h. Thereafter, kanamycin was added and grown
overnight. The overnight culture was centrifuged at 2000 rpm in a Beckman GS-15R
centrifuge using a plate rotor (Beckman Instruments, Palo Alto, Ca., USA). The
supernatant was transferred into a blocked 96-well microtitre plate and used in Fab
phage ELISA. DNA were prepared from the pellets from clones that were positive in
the ELISA and analyzed by restriction enzyme on agarose to identify clones that had
both heavy and light chain inserts.
2. 13 ELISA PROCEDURES
Microtitre plates (Coastar, Corning, Wiesbaden, Germany) were coated with equal
concentrations of antigens (600 ng/well) and kept in a humidified chamber at 4oC
overnight. Wells were blocked with 1% Casein-PBS for 1 h at 37 oC and incubated with
Fab phage supernatants for 1 h. Bound Fab phages were detected by HRP-conjugated
mouse anti-M13 phage antibodies (Pharmacia, Freiburg, Germany), and read in a
DYNATECH MR 5000 ELISA reader.
2. 14 DETERMINATION AND ANALYSIS OF NUCLEOTIDE AND AMINO
ACID SEQUENCES
Fab phage clones that were positive in the ELISA and had light and heavy chain DNA
inserts as determined by restriction enzyme analysis were cultured overnight in SB
medium containing carbenicillin. DNA preparations were done either by the Promega
Wizard Miniprep kit (Promega, Madison, WI) or Qiagen miniprep kit (Qiagen, Hilden,
Germany) according to the manufacturers instructions. Cycle sequencing reaction was
performed using Amersham cycle sequencing kit (Amersham, Braumscheig, Germany)
with infrared flourophore (IRD41)-labelled primers (MWG Biotech, Eberserg,
Germany) (Fischer et. al., 1999). The sequencing primers were PelB and SeqGb for the
heavy chains, and OmpA, SeqLb or SeqKb for the light chains , (Fischer et. al., 1999;
Jendreyko et. al., 1998; Graus et. al., 1997).
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Nucleotide sequences were analyzed with the MacDNAsis program, and manually
controlled by scf-files. Sequencing was repeated for ambiguous or unclear sequences.
Clones expressing functionally rearranged heavy and light chain sequences were further
evaluated by VBASE via the Internet (http://www.mrc-cpecam.ac.uk/imt-
doc/publicINTRO.html) using the program DNA-Plot developed by W. Muller and H.-
H. Althaus, University of Cologne, Germany for determination of germline segments
and mutations. To enable easy comparison of our findings with those of others in this
field, we applied the widely used Kabat definition of complementarity-detemining
regions (CDRs) and framework regions (FRs) as well as the V-BASE nomenclature.
Thus we used the full length of the germline V-genes in these calculations.
Table 1.2 Sequencing primers.
A. HEAVY CHAIN
(+) strand: SEQGb 5’- GTC GTT GAC CAG GCA GCC CAG -3 ’    (21-mer)
(-) strand: Pelb 5’- ACC TAT TGC CTA CGG CAG CCG - 3’    (21-mer)
B. LIGHT CHAIN
(+) strand: SEQkb 5’- ATA GAA GTT GTT CAG CAG GCA - 3’    (21-mer)
(+) strand: SEQlb 5’- GAA GTC ACT TAT GAG ACA ACA C - 3’  (22-mer)
(-) strand: OmpA 5’- AAG ACA GCT ATC GCG ATT GCA G - 3’  (22-mer)
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3. 0 RESULTS
3. 1 LIBRARY CONSTRUCTION
3. 1. 1 Isolation of RNA
107 cells/ml B lymphocytes - antibody producing cells - were isolated from 20 ml
peripheral blood from an 8-1/2 year-old girl (SH) suffering from acute myocarditis with
clinical signs of cardiac failure for library construction. She was diagnosed as a patient
suffering from systemic lupus erythematosus and rheumatic fever. The blood was drawn
24 days after the patient had had IVIG therapy. RNA from peripheral blood
lymphocytes after administration of IVIG would provide DNA dominated by currently
secreted specificities, as cells actively secreting antibodies will contribute substantially
more immunoglobulin RNA than from resting B cells that sit stationary in lymphoid
tissues (Persson, 1993). Total RNA was extracted from the B lymphocytes for cDNA
synthesis (Fig. 3.1).
                                             
M
28S
18S
Figure 3. 1. Gel electrophoregram of total RNA isolated from the peripheral blood lymphocytes of
a patient with SLE and rheumatic fever. The quality of undegraded total RNA is shown by the
double-sized 28S rRNA band to that of the 18S rRNA band. M, ΦX 174 molecular marker.
Since RNA molecules are unstable and denature readily, and since DNA molecules are
stable to handle in cloning, the RNA was reverse-transcribed into cDNA, for subsequent
use in PCR and routine cloning purposes.
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3.1.2 Amplification and cloning of Fd, λ, and κ chain genes
First strand cDNA syntheses in separate reactions (γ, κ and λ chains) were performed
using 3’ specific primers that were subsequently used in the PCR. To generate sufficient
amount of DANN for cloning, the cDNAa was first amplified in PCR. The PCR primers
are designed such that they incorporate restriction enzyme sites allowing for directed
cloning with the proper reading frame. Analysis of the heavy chain PCR products on 2
% agarose gel revealed bands of expected sizes between 660-680 bp. The varying
intensities may represent the level of expression of different antibody gene families
presented by the patient at the time the material was collected (Fig. 3.2).
M VH1   VH2   VH3     VH4     VH5     VH6    VH7    VH8     ConGa   Neg
    ~680 bp
    ~330 bp
    (positive
     control)
Figure 3. 2. Gel analysis of PCR amplified human genomic immunoglobulin heavy chain variable
region segment. Amplification conditions are described in the materials and methods. M, ΦX 174
molecular marker; VH1, …..VH8, family specific Ig genes; ConGa, positive control primer for
constant regions; Neg, negative control without template
The heavy chain PCR products were pooled, electrophoresed on 2% agarose, and the
expected size of the heavy chain fragments excised and purified from the gel, Fig. 3.3
(A) and (B). The fragments were restricted by the heavy chain restriction enzymes,
subjected to agarose gel electrophoresis, and finally purified from the agarose gel, Fig.
3.3 (C) and (D). Similarly, all light chain PCR fragments (kappa and lambda) were also
pooled, restricted, and purified from agarose.
The heavy and light chain PCR fragments were ligated into the pComb3H phagemid for
the construction of the SH library which contained 3.3 x 107 members. The pComb3H
phagemid used in this combinatorial library construction allow for display of the
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repertoire of cloned antibody fragments on the surface of helper phage (VSCM13), that
in its genome carries the corresponding antibody DNA.
(B)(A)
  M M
   ~680 bp
M  M(C) (D)
Figure 3. 3. 2 % agarose gel of, (A) pooled heavy chain PCR products, (B) gel showing excised
heavy chain PCR products, (C) Xho I/Spe I restricted heavy chain PCR products, and (D) gel
showing excised restricted heavy chain products. M is the molecular marker ΦX 174.
In a random screening, 7/10 (70 %) clones contained both heavy and light chain DNA
inserts as analysed by restriction enzyme analysis. Gene sequencing analysis of
randomly picked clones (unpanned or non-antigen selected)  from the unselected library
revealed that the heavy chain antibody genes were in the right reading frame, but many
of the light chain sequences had one or two stop codons in the reading frame. Therefore,
light chain shuffling was done by retaining the heavy chain of the original repertoire,
and new light chain genes were amplified and ligated into the plasmid. The new library
contained 6.9 x 107 members and 8/10 clones had both heavy and light chain fragments
as revealed by restriction enzyme analysis. To determine whether the unpanned SH
library contained many different clones, the diversity was monitored by digesting 12
individual clones with BstN1 (New England, Biolabs, Berverly, MA., USA) restriction
enzyme and the fragments analyzed on 2 % agarose (Fig. 3.4).
Each of the clones analyzed by BstN1 restriction had a distinct restriction pattern from
the other showing that the library was made up of different clones with diverse heavy
and light chain gene usage. Cloning of target genes results in the presence of ’clones of
interest’ and inevitably wildtype plasmids which outcompete the desired clones. In order
to successfully isolate clones that express antibody genes it was necessary to optimize
the unselected library before its usage.
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M1        1          2         3         4         5         6         7         8         9       10        11        12     M2
Figure 3. 4. BstN1 digestion of 12 randomly picked unselected clones from the library of patient
SH. BstN1 frequently cleaves in the V regions but only 2 sites in the pComb3H phagemid vector.
M1, 1 kb molecular marker; M2, ΦX 174 molecular marker.
3. 2 LIBRARY OPTIMIZATION
Agarose gel electrophoresis of the total DNA from the unselected (original) library
revealed 2 bands at or near the expected size of the library DNA (Figure 3. 5, lane 1).
More often, the presence of ’bald’ clones (clones containing no inserts but which have
selective growth advantage) in a library results in over-amplification of the these clones
to the disadvantage of clones containing inserts during further culture of the library
(Fischer et. al., 1999). To find out which of these 2 bands contain clones with heavy and
light chain inserts, the upper and lower bands were separately excised from the gel,
purified, restricted and analyzed on agarose.
Fig. 3.5 shows that the upper band contains both heavy and light chain inserts whilst the
lower band was ’bald’. Hence, the upper band was used to transform bacteria, and the
resultant library contained 5.6 x 106 members. This became the final constructed library
from the patient with systemic lupus erythematosus and rheumatic fever (SH library),
from which panning on an antigen (IVIG) resulted in the isolation of antigen specific
Fabs, as well as the isolation of unselected clones.
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Figure 3. 5. Restriction enzyme analysis of the original/unselected library to eliminated bald clones
from the original library (lane 1). Lanes 2 and 3 respectively, are the unrestricted upper and lower
bands purified from the original library. Lanes 4 and 6 show restricted heavy and light chain DNA
fragments from the unrestricted upper fragment band (lane 2). Lanes 5 and 7 show that the
unrestricted lower band (lane 3) contain no immunoglobulin chain DNA fragments. Xho I/Spe I
were the heavy chain restriction enzymes whilst the light chain restriction enzymes were Sac I/Xba
I. The molecular markers M1 and M2 have already been described in Figure 3. 4
3. 3 BIOPANNING ON IVIG
Panning of the SH library for monoclonal Fab phages bound by IVIG was performed
using 300µl of (30mg/ml) IVIG preparation (Sandoglobin, Sandoz, Basel, Switzerland)
which were coated in 5ml Nunc immunotubes. A selection strategy was used in which
the Fab phages were captured by the immobilized IVIG, and unbound phages washed
off. Bound phages were then eluted with HCl/glycine buffer pH 2.2, neutralized with
Tris HCL pH 9.0, and used to re-infect bacteria for propagation for the next rounds of
panning, until a highly enriched population of phages carrying IVIG specific Fabs were
obtained. The SH library was subjected to four rounds of panning on IVIG. To monitor
the progress of the panning procedure, the percent of phage recovered at every round, as
well as the enrichment of phages at a particular round over the previous were calculated
from the number of clones that were plated on phage input and output carbenicillin
plates, Table 3.1 (Siegel et. al., 1997).
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Table 3.1: Panning of phage displayed Fabs from SH combinatorial antibody library on IVIG
(After Siegel et. al., 1997).
Panning
round
Phage
Input (c.f.u)a
Phage
Output (c.f.u)b % Boundc Enrichmentd
1 2.8 x 1012 5.7 x 105 2.0 x 10-5 -
2 1.5 x 1012 3.9 x 105 2.6 x 10-5 x1.3
3 1.2 x 1012 2.6 x 106 2.2 x 10-4 x8.5
4 1.3 x 1012 9.8 x 106 7.5 x 10-4 x3.4
aNumber of colony forming units (c.f.u) of phage incubated with antigen
bTotal number of c.f.u of phage eluted after incubation with antigen
c(phage output/phage input) x 100 i.e. % phage bound (or recovered)
dFold increase (enrichment) in % bound phage compared to previous round of panning
Titration of phage input and output revealed that there was an enrichment of phages
bound by IVIG at every round of panning (from panning 1 to panning 4). There was a
38-fold increase in percent phage bound in panning 4 over that obtained during the first
round of panning. These data seemingly revealed that bacterial colonies that were
infected with phages from a previous round of panning resulted in the enrichment of
specific phage population expressing Fabs bound by IVIG. This gave the indication that
the possibility to isolate monoclonal Fabs bound by IVIG exists.
To isolate single clones producing monoclonal antigen-specific antibodies (Fabs bound
by IVIG), total DNA from the fourth round of panning need to be transformed into
bacteria. However, before the transformation, it was important to restrict the total DNA
obtained from the fourth round on panning on IVIG to ascertain that the population of
antibodies selected during the panning process contain both heavy and light chain
inserts. In addition, it is also worthwhile to perform a polyclonal Fab phage ELISA on
the antigen (IVIG) used in the selection process (panning) to gain a first hand
knowledge about the specificity of the selected phages in the biopanning process.
3. 4 POLYCLONAL FAB PHAGES BOUND BY IVIG
Though ’bald’ clones in the unselected library were ’eliminated’ or reduced as much as
possible during the optimization of the library (section 3.2, Fig. 3.5), the re-emergence
of such clones as well as clones with single inserts (light or heavy chain DNA, only)
which have growth advantage over clones with double inserts (heavy and light chain
DNA inserts) during various rounds of panning could not be underrated. Therefore, to
have an idea whether clones selected at the end of the panning process were clones
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containing both heavy and light chain DNA inserts before transforming bacteria for the
isolation of Fabs, the total DNA at the end of the last round of panning (panning four)
was subjected to both heavy and light chain restriction enzyme analysis, and compared
with the total DNA from the unselected library, Fig. 3.6
As visualized on the agarose gels, both Figures 3.6 (A) and (B) show that the IVIG-
selected clones contain both antibody heavy and light chains DNA inserts of expected
sizes of approximately 680 bp. After the digestion of the total DNA from panning 4 but
before transforming bacteria with it for isolation of monoclonal Fab phages, it was also
necessary to verify whether the selected clones during the panning process contained
phages that bind IVIG. This was important to establish that the selected library is not
full of ’plastic-binding’ phages which inevitably are present in a library (Adey et. al.,
1995). This was done by polyclonal Fab phage ELISA in IVIG-coated wells for the
unselected library, as well as the selected libraries for all four rounds of panning on
IVIG (Fig. 3.7).
Figure 3. 6. Enzymatic double restriction. (A) Total unselected library DNA, (B) total DNA IVIG
panning IV. Restriction enzymes: light chain - Sac I/Xba I; heavy chain -  Xho I/Spe I. M1, M2
molecular markers described in Figure 3.4
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Figure 3. 7. ELISA of polyclonal phages of the unselected (unpanned) repertoire of the systemic
lupus erythematosus and rheumatic fever library, and selected against IVIG in panning round 1
(IVIG I), panning round 2 (IVIG II), panning round 3 (IVIG III), and panning round 4 (IVIG IV).
Coated proteins consisted of IVIG as well as PBS/1% casein blocking buffer to detect nonspecific
binding. Bound Fab-phages were detected with HRP-labeled anti-M13 antibodies. Results are
expressed as absorbance at 405 nm with a multiscan automatic plate reader (MR5000, Dynatech
Labs, Chantily, VA., USA)
Typical IVIG binding phage enrichment were observed from panning 1 to 4. As can be
seen in figure3.7, the initial ’high’ background on PBS (plastic binding clones) gradually
decreased from panning 1 to panning 4 indicating that the stringency of washing led to
the retention of Fab phages specifically bound by IVIG. Only a few of sticky, non-
specific binders remained after round four of panning. These phages were present at a
much higher proportion in the unselected repertoire. This also demonstrated one of the
objectives of the Fab phage panning method, that is to say, to increase the ’signal-to-
noise ratio’ of specific versus non-specific binding ratio during the selection process
(Siegel et. al., 1997). This result indicated that there was a probable chance of
successful isolation of monoclonal Fabs bound by IVIG which would lead to their
further characterization.
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3. 5 ISOLATION OF MONOCLONAL FAB PHAGES BOUND BY IVIG
Total DNA from panning 4 was used to transform bacteria and individual colonies were
picked and grown for 5 - 6 h, and super-infected with VCSM13 helper phage for Fab-
phage rescue. This allowed for the display of cloned antibody fragments on the surface
of phage particles that in its genome carries the corresponding antibody DNA. Culture
supernatants from individual colonies from the fourth round of panning were analyzed
for their reactivity with IVIG in ELISA. Plasmid DNA from positive clones were
digested by restriction enzymes and analyzed by agarose electrophoresis. Clones that
contain both heavy and light chain inserts (data not shown) were sequenced and only
clones that contain functional heavy and light chain antibody variable region sequences
were used further in the study. Representative clones showing specific reactivity to
IVIG are shown in figure 3.8. This results also show that the panning procedure finally
resulted in a highly enriched population of phage carrying specific antibody fragments
with ’little’ or ’minimal’ unspecific binding.
One of the aims of this study was to compare the IVIG-binding Fabs isolated from the
patient (SH) with rheumatic fever and systemic lupus erythematosus to those isolated
from 3 patients with idiopathic thrombocytopenic purpura (Fischer et. al., 1999;
Jendryeko et. al., 1998) cloned in our laboratory. One of the patients developed SLE.
The IVIG-binding Fabs from patient SH was tested for their reactivity to human Fc
fragments. Rheumatoid factors are antibodies that bind to the Fc portion of IgG
immunoglobulins. They are found in patients with arthritis as well as patients with
inflammatory and infectious diseases. Rheumatoid factors are also found in healthy
people following immunization suggesting that they may play a role in normal immune
functions such as in the clearance of circulating immune complexes (Potter and Capra,
1995). Rheumatoid factors in idiopathic thrombocytopenia are thought to stabilize
(enhance) low affinity anti-platelet antibodies in binding to platelets. Yang et. al. (1999)
postulated that some IgG components in IVIG interact with these IgG rheumatoid
factors and thus interfere with their enhancing effects on anti-platelet antibodies.
None of the IVIG-binding Fabs from the patient with systemic lupus erythematosus and
rheumatic fever library bound Fc fragments (figure 3.8) in contrast to IVIG-binding
Fabs isolated from patients with idiopathic thrombocytopenic purpura (Fischer et. al.,
1999; Jendryeko et. al., 1998).
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Figure 3.8. ELISA of representative individual (monoclonal) Fab-phage antibodies obtained after
the fourth round of panning on IVIG. Wells were coated with IVIG, Fc fragments and PBS/1%
Casein blocking buffer. Negative controls were pComb3H transfected E. coli phage supernatant
(pComb3H), and SB medium containing VCSM13 helper phage (SB+M13). Bound Fab-phages
were detected with HRP-labeled anti-M13 antibodies. Results were expressed as under Figure 3. 7.
Clones selected repetitively included SH8 and SH44 (2X each); SH21 (9X), and SH89 (7X).
As a further step in characterizing and comparing the IVIG-binding Fabs isolated from
patient SH to those from the patients with idiopathic thrombocytopenic purpura, the
Fabs from SH was tested for their binding to platelets. Since platelets require a different
surface (for coating) from IVIG for ELISA, the testing of the Fabs for their reactivity to
platelets was done in a separate ELISA.
3. 6 REACTIVITY OF IVIG-BINDING FABS ON PLATELETS
Idiopathic thrombocytopenic purpura is mediated by autoantibodies that react to
antigens expressed on platelets leading to their clearance by phagoctosis.
Thrombocytopenia and platelet dysfunction are frequently found in patients with SLE,
in particular, in association with anti-platelet antibodies. These antibodies react with the
major platelet glycoproteins, gpIIb-IIIa, interfering with platelet aggregation and
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adhesion (Xu et. al., 1995). To compare the extent of the repertoire used by the Fabs
bound by IVIG from the library generated from the patient with systemic lupus
erythematosus/rheumatic fever (SH) library, to that from the patients with autoimmune
thrombocytopenia, the panel of selected Fabs from the SH library were tested also for
binding to platelets in ELISA. IVIG-binding Fabs with reactivity to platelets had earlier
been isolated from patients with autoimmune thrombocytopenia (one of whose illness
progressed to SLE) in our group.
Figure 3.9 Summary of two repetitive ELISAs with representative Fab phage supernatants of
sequenced clones after the 4th round of panning with IVIG on human platelets. 50 µl/well of 3 x 107
cells/ml of purified platelets were coated by drying to flexible plates (Microtest III, Falco, Oxnard,
California). Incubation with Fab phages and further development were as described for the IVIG
ELISA. The blood group was A, Rh positive. Shown is the mean A450/650 after subtraction of the
background staining on PBS/Casein coated wells. Positive controls were LO31 (V3-30 locus)  and
NK22 (V4-b locus), platelet-binding IVIG-derived Fabs from patients with autoimmune
thrombocytopenia (Fischer et. al., 1999). Negative controls were pComb3H transfected phage
supernatant (pComb3H) and SB medium containing VCSM13 helper phage (SB + M13). Bound
Fab phages were detected with HRP-labeled anti-M13 antibodies.
None of the SH library IVIG-binding Fabs bound platelets. IVIG has a weak interaction
with clone LO31, which was isolated from a patient with autoimune thrombocytopenia
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whose illness progressed to SLE (Jendreyko et. al., 1998; Fischer et. al., 1999). To
analyze the IVIG-binding Fabs further, the DNA were sequenced. The sequencing
showed that indeed full length antibody DNA has been cloned. This permitted their
further characterization.
3. 7  HEAVY CHAIN AMINO ACID HOMOLOGY
Sequencing of clones that were positive in the IVIG monoclonal Fab phage ELISA
revealed 23 clones that had both functional heavy and light chain genes. Amino acid
homology tree was constructed to show that the sequences were different from each
other. Four individual clones were repetitively selected, these varied from two to nine,
figures 3.10 and 3.11.
SHgi44-AA
SHgi58-AA
SHgi55-AA
SHgi08-AA
SHgi21-AA
SHgi51-AA
SHgi89-AA
88.1%
83.4%
81.6%
79.8%
78.3%
69.2%
Figure 3. 10. Amino acid homology tree of representative VH Fab phages bound by IVIG from the
SH library constructed by the McDNASIS software. Clones SH8 and SH44 (2X each), SH21 (9X),
and SH89 (7X) were repetitively selected.
Comparison of the complete overlapping heavy chain amino acid sequences between all
seven individual VH 3 family Fab phage loci bound by IVIG showed that Fabs 44 and
58 were the most closely related (88.1%) whilst the lowest homology was with Fab 89
(69.2%).
SHli55-AA
SHli08-AA
SHli89-AA
SHli21-AA
SHli51-AA
SHli44-AA
SHli58-AA
87.7%
69.5%
54.7%
61.5%
42.2%
25.3%
Figure 3. 11. Amino acid homology tree of representative VL Fab phages bound by IVIG from the
SH library constructed by the McDNASIS software. Clones SH8 and SH44 (2X each), SH21 (9X),
and SH89 (7X) were repetitively selected.
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The light chain amino acid homology revealed that the most closely related Fabs were
clones 55 and 8 which shared a homology of 87.7% whilst the lowest homologous clone
was clone 58 (25.3%).
3. 8 VH AND VL GENE SEGMENT USAGE OF IVIG SPECIFIC FABS
The variable region gene sequences from the Fab phages were aligned to human
germline variable region sequences compiled in the VBASE directory to assign them to
their closest germline counterparts with the aid of the DNAPLOT alignment software. A
homology table was built to categorize the variable region genes into families, loci, and
their deviation from their closest germline gene, table 3. 2. The D and JH genes of each
Fab are also provided. With regard to VH gene usage, only two VH3 germline genes
were selected, namely V3-23 and V3-30, with 3-23 being the most frequently used
16/23 (70%). These two VH loci genes were the most frequently observed in IVIG-
bindig Fabs from patients with autoimmune thrombocytopenia (Fischer et. al., 1999;
Jendreyko et. al., 1998). Comparison of the 3-23 heavy chain sequences with known VH
germline sequences revealed less divergence from the closest VH germline genes with
homologies ranging between 96.7-99.6 %. The remaining 7/23 (30%) derived their VH
loci from the gene segment V3-30, sharing 99.6% homology with their closest germline
gene. Comparison of the SH IVIG Fab phages light chain variable region sequences
with their closest germline gene segments revealed that the Vλ1, Vλ2, Vλ3, and Vκ2
families were represented. Among these, the VL 3 family predominated with about
19/23 (83%) clones being represented. Unlike the VH segments where only two VH loci
were used, the light chain gene segments were derived from 4 different VL loci.
3. 9 SH NON-ANTIGEN SELECTED (UNPANNED) CLONES
5 non-antigen or unpanned clones were sequenced to determine the diversity of the
systemic lupus erythematosus and rheumatic fever library (Table 3.2). 4 clones
belonged to the VH 3 family but only 1 (clone SH-u8a) was derived from the 3-23 locus
compared with the IVIG binders where 16/23 were from this locus. The unselected
clone SH-u8a, used a similar V-D-J rearrangement to that of the IVIG-selected clone
SH-55. Nevertheless, they were two different clones as each paired with light chains
from different VL families. The VH region segment from one non-antigen selected clone
(SH-u2b), was not assigned to any particular locus after the database search. This clone
however, paired with an identical light chain that was observed with nine (V 3-23) IVIG
Fab clones. Another unpanned clone (SH-u3a) that belongs to VH1 family paired with a
λ light chain that utilized a λ gene segment identical to that of the IVIG binders that
used the VH 3-30 loci. The Vλ gene usage from the unpanned clones were Vλ1, Vλ2,
Vλ3, and Vλ6.
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Table 3. 2 Putative germline sequences of SH IVIG-selected and non-antigen selected antibody  heavy
and light chain variable regions from the patient with systemic lupus erythematosus and rheumatic
fevera
Clone VH
family
VH VH
locus
Hom-
ology
%†
D JH VL
family
VL VL
locus
Hom-
ology
%†
JL
IVIG-selected Fab phages
SH8‡ 3 DP-47/V3-
23…+
(Z12347)*
3-23 97.4 D6-19
(X97051)
JH4b
(X86355)
VL3 DPL16/VL3.1
…+ (Z22202)
3l 99.2 JL2/JL3a
(M15641)
SH21‡ 3 DP-47/V3-
23…+
(Z12347)
3-23 99.6 D4
(J00232)
JH3b
(X86355)
VL3 IGLV3S2+
(X71966)
3h 99.2 JL3b
(D87017)
SH44‡ 3 DP-47/V3-
23…+
(Z12347)
3-23 97.4 D2-
8/DLR1
(X97051)
JH4b
(X86355)
VL2 2b2.400B5+
(Z73665)
2b2 91.7 JL2/JL3a
(M15641)
SH51 3 DP-47/V3-
23…+
(Z12347)
3-23 96.7 D4-
11/DA1
(X97051)
JH4b
(X86355)
VL1 DPL7/VL1.2
(IGLV1S2)+
(Z22193)
1e 99.6 JL3b
(D87017)
SH55 3 DP-47/V3-
23…+
(Z12347)
3-23 97.0 D6-25
(X97051)
JH4b
(X86355)
VL3 DPL16/VL3.1
…+ (Z22202)
3l 98.5 JL3b
(D87017)
SH58 3 DP-47/V3-
23…+
(Z12347)
3-23 99.3 D3-
3/DXP4
(X97051)
JH1
(J00256)
VK2 DPK18/A17+
(X93635)
A17 97.8 JK2
(J00242)
SH89‡ 3 DP-
49/1.9III…
+ (Z12349)
3-30/
3-
30.5
99.3 D3-
22/D21-9
(X97051)
JH6b
(X86355)
VL3 3r.9C5/DPL23
…+ (Z73647)
3r 99.6 JL2/JL3a
(M15641)
Randomly picked clones from the unpanned SH library
SHu2a 3 DP-48/13-
2+
(Z12348)
3-13 94.8 D6-19
(X97051)
JH5B
(X86355)
VL2 2c.118D9/V1-
2+ (X97462)
2c 95.9 JL2/JL3a
(M15641)
SHu8a 3 DP-47/V3-
23…+
(Z12347)
3-23 97.4 D6-25
(X97051)
JH4b
(X86355)
VL6 6a.366F5/V1-
22…+
(Z73673)
6a 98.1 JL2/JL3a
(M15641)
SHu2b 3 p6
(M77305)
- 94.4 D4
(J00232)
JH4b
(X86355)
VL3 IGLV3S2+
(X71966)
3h 96.4 JL3b
(D87017)
SHu3b 1 DP10/hv10
51…+
(Z12312)
1-69 97.0 D5-
12/DK1
(X97051)
JH6b
(X86355)
VL3 3r.9C5/DPL23
…+ (Z73647)
3r 89.7 JL2/JL3a
(M15641)
SHu7b 3 DP-38/9-
1…+
(Z12338)
3-15 99.0 D3-
10/DXP,1
(X97051)
JH4b
(X86355)
VL1 1b.366F5/DPL
5…+
(Z73661)
1b 96.4 JL2/JL3a
(M15641)
*Numbers in parenthesis indicate European Molecular Biology Laboratory/GenBank accession numbers. Sequences are named
according to the VBASE databank. Dots indicate abbreviated names and/or existence of synonyms; + indicates a mapped
chromosomal location.
†Homology of the variable region genes
‡Clones selected repetitively included SH8 and SH44 (2X each); SH21 (9X), and SH89 (7X)
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3. 12 MUTATION RATES
A table of mutation rates (Table 3.3) was built to show where in the variable region
(CDRs and FRs), the deviation (i.e. < 100% homology) from their germline
counterparts observed in the previous section, occured for each clone. Somatic
hypermutations leading to a single base substitution may either lead to replacement (R)
of an amino acid or remain silent (S) if the resulting codon encodes for an identical
amino acid. R/S ratios above 2.9 are considered high and indicative of antigen selection.
However, the role of CDR3 which lies at the center of the antigen-binding site is
difficult to access and were not included in this type of analysis. In addition, the first
eight codons of the FR1 region were excluded from the analysis of somatic mutations
because this region is complementary to the primers used for amplification (see figures
3.12 and 3.13) . Sequences from representative clones for the 23 Fabs were aligned on
themselves to reveal individual variations among the clones (figures 3.12 and 3.13)
30 40 50
SHgi44-AA 1 EVQLLE-SGG GLVQPGGSLR LSCAASGFTF SSYAMSWVRQ APGKGLEWVS 50
SHgi58-AA 1 EVQLLE-SGG GLVQPGGSLR LSCAASGFTF SIYAMSWVRQ APGKGLEWVS 50
SHgi55-AA 1 EVQLLE-SGG GLVRPGGSLR LSCAASGFTF SSYAMSWVRQ APGKGLEWVS 50
SHgi08-AA 1 EVQLLE-SGG GLVQPGGSLR LSCAASGFPF SNSAMSWVRQ APGKGLEWVS 50
SHgi21-AA 1 EVQLLEQSGG GLVQPGGSLR LSCAASGFTF SSYAMSWVRQ APGEGLEWVS 50
SHgi51-AA 1 EVQLLE-SGG GLVQPGGSLR LSCAASGFTF RSYDMTWVRQ APGKGLEWVS 50
SHgi89-AA 1 EVQLLEQSGG GVVQPGRSLR LSCAASGFTF SSYGMHWVRQ APGKGLEWVA 50
80 90
SHgi44-AA 51 AISGSGGSTY YADSVKGRFT ISRDNAKNSL YLQMNSLRAE DTAVYYCARD 100
SHgi58-AA 51 AISGSGGSTY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCAKG 100
SHgi55-AA 51 AISGSGGSTH YADSVKGRFT ISRDNSKNTL CLQMNSLRAE DTALYYCARS 100
SHgi08-AA 51 SISGSGGSTY YADSVKGRFT ISRDNSKNTL SLQMNSLRAE DTAVYYCAKG 100
SHgi21-AA 51 AISGSGGSTY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCAKD 100
SHgi51-AA 51 GISGSGDRTY YADSVKGRFT ISRDNSKSTL YLQMNSLRAE DTAVYYCARR 100
SHgi89-AA 51 VISYDGSNKY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCAKD 100
120 130 140 150
SHgi44-AA 101 -----RG-ER --TFDIWGQG TMVTVSS... .......... .......... 150
SHgi58-AA 101 -----AL-GG --YYTHWGQG TLVTVSS... .......... .......... 150
SHgi55-AA 101 -----VYYGG --YLDYWGQG TLVTVSS... .......... .......... 150
SHgi08-AA 101 -----GSSSG PYHFEYWGQG TLVTVSS... .......... .......... 150
SHgi21-AA 101 HLGYCSSTSC RGAFDIWGQG TMVTVSS... .......... .......... 150
SHgi51-AA 101 Q------SRG RGAFDYWGQG TLVTVSS... .......... .......... 150
SHgi89-AA 101 LSPFYDSSA- ---MDVWGQG TAVTVSS... .......... .......... 150
CDR1
 >CDR3
 <CDR3
CDR2
PCR-Pimer
 *        *               * * *     *        *       *     * *
 *     *     *
Figure 3. 12. Alignment of VH amino acids of representative clones SH8, 21, 44, 51, 58, and 89 from
IVIG-selected Fabs according to their highest homology. Complementarity determining regions
(CDRs) according to the Kabat definition are indicated (Kabat et. al., 1991). The beginning of the
sequences (ca. 8 amino acids) was determined by the PCR primers. * = critical amino acid positions
known for binding to staphylococcal protein A (SpA) Graille et. al., 2000). The sequences are
designated according to the library from which they were obtained, i.e., SH is the initials of the
patient; g means IgG heavy chain; i means (IVIG), the antigen used in isolating the antibody. These
sequence data are available from the European Molecular Biology Laboratory nucleotide sequence
database under accession numbers AJ298606 - AJ298612.
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The VH CDR3 regions displayed an overall high degree of variation in length and
sequence, ranging between nine (e.g. SHgi44) and 17 (SHgi21) amino acids.
20 40 50
SHli55-AA 1 ELQDPVVS-- VALGQTVRIT CQG--DSLRS YY-A--SWYQ QRPGQAPVLV 50
SHli08-AA 1 ELQDPVVS-- MALGQTVRIT CQG--DSLRS YY-A--SWYQ QKPGQAPVLV 50
SHli89-AA 1 ELQPPSVS-- VSPGQTASIT CSG--DKLGD KY-A--CWYQ QKPGQSPVLV 50
SHli21-AA 1 ELQPPSVS-- VAPGRTARIT CGG--NNIGS KS-V--HWYQ QKPGQAPVLV 50
SHli51-AA 1 ELQPPSVS-- GAPGQRVTIS CTGSSSNIGA GYDV--HWYQ QLPGTAPKLL 50
SHli44-AA 1 ELQPASVS-- GSPGQSITIS CTGTSNDIAD YNHV--SWYR QDPGKVPKLM 50
SHli58-AA 1 ELTQSPLSLP VTLGQPASIS CRSGQSLVHS DGNTYLNWFQ QRPGQSPRRL 50
70 80 90
SHli55-AA 51 IYAENTRPSG IPDRFSGSSS GNTASLTITG AQAEDEADYY CNSRDSSGNH 100
SHli08-AA 51 IYGKNNRPSG IPDRFSGSSS GNTASLTITG AQAEDEADYY CNSRDSSGNH 100
SHli89-AA 51 IYQDSKRPSG IPERFSGSNS GNTATLTISG TQAMDEADYY CQAWDSSTAH 100
SHli21-AA 51 IYYDSDRPSG IPERFSGSNS GNTATLTISR VEAGDEADYY CQVWDSSSDH 100
SHli51-AA 51 IYGNSNRPSG VPDRFSGSKS GTSASLAITG LQAEDEADYY CQSYDSSLSG 100
SHli44-AA 51 IYDVTGRPSG VSNRFSGSKS GNTASLTISG LQADDESIYY CSSYTHGVT- 100
SHli58-AA 51 IYKVSNRDSG VPDRFSGSGS GTDFTLRISR VEAEDVGVYY CM---QGTHW 100
110 120 130 140 150
SHli55-AA 101 LSVFGGGTKL TILG...... .......... .......... .......... 150
SHli08-AA 101 V-VFGGGTKL TVLG...... .......... .......... .......... 150
SHli89-AA 101 V-VFGGGTKL TVLG...... .......... .......... .......... 150
SHli21-AA 101 L--FGGGTKL TVLG...... .......... .......... .......... 150
SHli51-AA 101 SWVFGGGTKL TVLG...... .......... .......... .......... 150
SHli44-AA 101 ---FGGGTKL TVLV...... .......... .......... .......... 150
SHli58-AA 101 PYTFGQGTKL EI-K...... .......... .......... .......... 150
CDR1
CDR2 > CDR3
<CDR3
PCR -Primer
Figure 3. 13. Alignment of VL amino acids of representative clones SH8, 21, 44, 51, 58, and 89 from
IVIG-selected Fabs according to their highest homology. Complementarity determining regions
(CDRs) according to the Kabat definition are indicated (Kabat et. al., 1991). The beginning of the
sequences (ca. 8 amino acids) was determined by the PCR primers. The sequences are designated
according to the library from which they were obtained, i.e., SH is the initials of the patient; l
means a light chain; i means (IVIG), the antigen used in isolating the antibody.  These sequence
data are available from the European Molecular Biology Laboratory nucleotide sequence database
under accession numbers AJ298613 - AJ298619.
The pattern of somatic mutations in the CDR1 and CDR2 of the VH genes was
indicative of replacement events in four Fabs namely SH8, 51, 55, and 58 with a high
R/S ratio of >2.9 (Table 3.3 Mutation Rates). The remaining three Fabs had 0 R/S
ratios. Two light chains, SH25 and SH55 had a higher R/S ratio >2.9 in the entire VL
CDR1 and CDR2. On the whole, only two Fabs displayed a R/S ratio >2.9 over the
entire VH region (SH51 and SH55) whilst one Fab (SH44) had a R/S ratio above 2.9 in
the entire VL region.
Analysis of the VH and VL genes in this study and earlier reports (Jendreyko et. al.,
1998; Fischer et. al., 1999; Hoffman et. al., 2000) revealed that the interaction of IVIG
49
with the Fabs might be dependent on the heavy chain since the light chains were from
diverse families. In some cases, the Fabs bound by IVIG had no functional light chains.
The interaction of IVIG with Fabs solely from the VH3 family in this study was
characteristic of the interaction of B cell superantigens with immunoglobulins from the
VH3 family (Silvermann, 1997). Thus, we next tested the IVIG-binding Fabs for their
reactivity with B cell superantigens.
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Table 3.3. Mutation rates in Variable region genes*
VH CDRs 1 and 2 VH FRs 1 - 3
Entire VH
region VL CDRs 1, 2, (3) VL FRs 1 - 3
Entire VL
region
Clone No./total no.  (%) R/S (ratio) No./total no.  (%) R/S (ratio) No./total no.  (%) No./total no.  (%) R/S (ratio) No./total no.
(%)
R/S (ratio) No./total no.  (%)
IVIG-selected Fab phages
SH8† 4/66 (6.1) 3/1 (3) 3/204  (1.5) 1/2 (0.5) 7/270  (2.6) 0/78   (0) 0    (0) 2/177  (1.1) 1/1 (1) 2/225    (0.8)
SH21† 0/66  (0) 0     (0) 1/207  (0.5) 1/0 (∞) 1/273    (0.4) 1/78    (1.3) 0/1 (0) 1/177   (0.6) 1/0 (∞) 2/225    (0.8)
SH44† 0/66  (0) 0     (0) 7/207  (3.4) 4/3 (1.3) 1/273    (2.6) 12/75  (16.0) 9/3 (3) 9/177   (5.1) 6/3 (2) 21/252  (8.3)
SH51 5/66  (7.6) 5/0  (∞) 4/204  (2.0) 3/1 (3.0) 9/270    (3.3) 1/93    (1.1) 0/1 (0) 0/180   (0) 0    (0) 1/273    (0.4)
SH55 1/66  (1.5) 1/0  (∞) 7/204  (3.4) 4/3 (1.3) 8/270    (3.0) 3/84    (3.6) 3/0 (∞) 1/177   (0.6) 1/0 (∞) 4/261    (1.5)
SH58 1/66  (1.5) 1/0  (∞) 1/204  (0.5) 1/0 (∞) 2/270    (0.7) 5/90    (5.6) 2/3 (0.7) 1/186   (0.5) 1/0 (∞) 6/276    (2.2)
SH89† 1/66  (1.5) 0/1  (0) 1/207  (0.5) 0/1 (0) 2/273    (0.7) 1/78    (1.3) 0/1 (0) 0/177   (0) 0    (0) 1/255    (0.4)
Randomly picked clones from the unpanned SH library
Shu2a 7/63  (11.1) 7/0  (∞) 7/204  (3.4) 4/3 (1.3) 14/264  (5.3) 8/90   (8.9) 7/1 (7.0) 3/180   (1.7) 1/2 (0.5) 11/270 (4.1)
Shu8a 2/66  (3.0) 2/0  (∞) 5/204  (2.5) 2/3 (0.7) 7/270    (2.6) 2/84   (2.4) 2/0 (∞) 1/186   (0.5) 1/0 (∞) 3/270   (1.1)
Shu2b 6/66  (9.1) 4/2  (2.0) 9/204  (4.4) 6/3 (2.0) 15/270  (5.6) 5/72   (6.9) 3/2 (1.5) 4/177   (2.3) 3/1 (3.0) 9/249   (3.6)
Shu3b 4/66  (6.1) 4/0  (∞) 4/201  (2.0) 3/1 (3.0) 8/267    (3.0) 10/66 (15.2) 8/2 (4.0) 15/177 (8.5) 8/7 (1.1) 25/243 (10.3)
Shu7b 4/72  (5.6) 4/0  (∞) 2/204  (1.0) 0/2 (0) 6/276    (2.2) 4/75   (5.3) 3/1 (3.0) 5/174   (2.9) 4/1 (4.0) 9/249   (3.6)
    *CDRs = complementarity determining regions; FRs = framework regions; no./total no. = number of mutations/total number of bases in the region; (%) = percent;
    R/S = number of replacement mutations/number of silent mutations; ratio = R/S ratio; ∞ = infinity (mathematically incorrect).
   †Clones selected repetitively included SH8 and SH44 (2X each), SH21 (9X), and SH89 (7X). Refer Table 3.2 for other definitions.
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3. 13. BINDING OF IVIG-SELECTED FABS TO KNOWN B CELL
SUPERANTIGENS
A control study involving an investigation of IVIG Fabs from IgG and IgM phage
display libraries from a healthy individual, and the results observed in this study as well
as in previous studies involving interaction of IVIG with Fabs from 3 patients with
autoimmune thrombocytopenia indicated that the preferential binding of IVIG to Fabs
from the V3-23 and V3-30 loci might not be related to the healthy state of the donor or
treatment with IVIG. Rather it was indicative of the unique binding of B cell
superantigens to immunoglobulins from the VH3 family. This prompted us to examine
the binding of the Fabs to Staphylococcal protein A (SpA) and HIV-1 gp120, two of the
most characterized B cell superantingens (Silverman, 1997).
Fig. 3. 14 Summary of ELISAs with Fab phage supernatants comparing the binding to IVIG and
the B cell superantigens staphylococcal protein A (SpA) and gp120. The VH germline origins of the
Fabs are indicated. Each specific A450 was calculated by subtracting the value obtained for
pComb3H phage supernatants on the respective antigen from the measured A450. Values on IVIG
and SpA for clones marked with * were obtained in a second ELISA with appropriate controls, and
all values on gp120 were obtained in an independent assay. However, all relative values were
confirmed repeatedly in independently assays. SHu7b is a V3-15 unselected control Fab. GG30a is
a V4-61 derived platelet-reactive IVIG binder isolated from a patient with idiopathic
thrombocytopenic purpura. (Jendryeko et. al., 1998). M1-10 is a V3-30 unselected control Fab from
a patient with Kawasaki disease (Leucht et. al., 2001).  This clone has an amino substitution of
glutamine (E) for lysine (K) at position VH57.
As demonstrated in Fig 3.14, some of the IVIG-selected Fab phages (SH8, SH44, and
SH51) displayed a very strong binding to SpA, whilst interactions with gp120 were
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weak. Except SH44, binding to SpA did not correlate to binding with IVIG, for
example, clones SH8 and SH51 showed stronger reaction to SpA than to IVIG. On the
other hand, clones SH21(62), SH55, SH58, and SH89, showed higher binding to IVIG
than SpA. Fab GG30a which is a VH4 family clone was negative on SpA, this is not an
unexpected result. SH7ub an unselected clone, was nearly negative on IVIG but clearly
bound SpA.
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4. 0 DISCUSSION
4.1 GENERAL REMARKS
Molecular analyses of phage-displayed antibody Fab fragments bound by IVIG cloned
from patients with autoimmune thrombocytopenia in our laboratory often originated
from the V3-23 and V3-30/3-30.5 VH germline genes (Fischer et. al., 1999; Jendreyko
et. al., 1998). One of the autoimmune thrombocytopenic patients’ illness progressed to
systemic lupus erythematosus (SLE). Furthermore, the same germline genes were also
observed to be the most frequently used VH genes for Fabs bound by IVIG from a
library constructed from a patient with Kawasaki disease (Leucht et. al., 2001), and also
from a healthy individual in a control study (Hoffmann et. al., 2000). The aim of this
study was to learn more about the interaction of IVIG with Fabs by analyzing at the
molecular level, Fabs bound by IVIG from a phage display library constructed from a
patient with  SLE and rheumatic fever, and at the same time compare these Fabs to
those from the autoimmune thrombocytopenic patients.
4.2 GENETIC ORIGIN OF IVIG-SELECTED HEAVY AND LIGHT CHAINS
The library for this study was constructed from peripheral blood lymphocytes isolated
from an 8-1/2 year-old girl. The blood was drawn 24 days after the patient had
undergone IVIG therapy. The combinatorial antibody library system, instead of
engineering single antibodies, creates millions of different clones by random processes
and use the powerful selection panning process to isolate antibodies with the desired
characteristics (Persson, 1993). However, the technique is not without problems.
Plastic-binding clones which often are enriched over desired clones during the panning
process makes it difficult to isolate antigen-specific clones. One of the factors that
contributed to the success of this study was the ’elimination’ of (as much as possible)
bald clones that had no light and heavy chain DNA fragments. This optimization step
during the library construction contributed heavily to the isolation of unselected clones
with both functional heavy and light chain genes and paved the way for completion of
the study. A total of 23 Fab phages bound by IVIG were isolated and characterized. The
VH sequences from all 23 antibodies bound by IVIG were derived from two putative
germline genes namely V3-23 and the V3-30/3-30.5 polymorphic variant. In contrast,
the VH sequences from five unselected clones were derived from at least five different
VH region loci. There were no specific enrichment of a particular light chain loci as
observed for the heavy chain. This purported to show that the heavy chain may be the
major target of IVIG during the selection process, since IVIG-selected Fabs devoid of
light chains, or those without functional light chains have been isolated before in our
laboratory (Leucht et. al., 2001; Hoffmann et. al., 2000).
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None of the IVIG-binding Fabs from the library of the patient with systemic lupus
erythematosus and rheumatic fever bound platelets, in contrast to IVIG-binding Fabs
isolated from patients with idiopathic thrombocytopenic purpura (Fischer et. al., 1999;
Jendryeko et. al., 1998). 8 of 16 Fab fragments from the three libraries constructed from
the patients with thrombocytopenia bound platelets, though the majority of them were
derived from the VH4 family (Fischer et. al., 1999). This perhaps suggest that the
platelet-specific antibodies from the patients with thrombocytopenia were those that
were relevant for the disease at the time the material was obtained. Mutation rates
varied between the extremes of zero to high replacement rates, and CDR3 composition
was between short to long residues. The mechanisms of replacement mutations which
are thought to be initiated by unknown antigen selection may influence binding through
the positioning of side chains that contact antigen, or by providing new contact residues
in the antigen combining sites, or by replacing repulsive or low affinity residues with
more favorable contact residues (Hoogenboom, 1997).
4.3 BIASED VH GENE REPRESENTATION IN THE Ig REPERTOIRE
The V3-23 and V3-30/3-30.5 genes have been observed to be the most frequently
rearranged and expressed VH gene in the immune repertoire (Matsuda et. al., 1998;
Cook and Tomlinson, 1995). It has been observed that there is not an equal
representation of the various VH families in the fetal and adult repertoire. The immune
system is biased with some VH families being over-represented and others under-
represented. The known maximum number of functional segments of the human
immunoglobulin heavy chain repertoire is 51 (Cook and Tomlinson, 1995), though
another study by Matsuda et. al. (1998) reported 44 functional genes. The difference
between these two studies is attributed to insertion/deletion polymorphism which when
present results in the gain of some functional genes. 22 VH3 family segments account
for 43.1 % of the 51 functional VH segments (Tomlinson, 1997). Some genes, such as
V3-23 and V3-30 have been demonstrated to be over-represented at all stages of B cell
development. The V3-23 gene which is well represented in the fetal repertoire and
comprising about 25 % of all VH3 clones in the normal adult peripheral B cells, is
present in all individuals tested (Kraj et. al., 1997). De Wildt et. al., (1999)
investigating the pairings of VH and VL chains from 365 human IgG+ B cells observed
that the most frequently utilized VH germline genes were from the V3-23 and V3-30/3-
30.5 locus. In a large study involving more than 4,500 independent VH3 family gene
segments from 12 unrelated individuals, Huang et. al. (1996) observed that V3-23 and
V3-30 were most frequently expressed in the normal repertoire with mean
representations of 24.3 % and 16.1 % respectively. The significance of the study
affirmed that the representation of the adult repertoire is not by random VH
rearrangement by which the frequency of utilization of variable region segments of a
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family may be proportional to family size/complexity. In a more recent study, the V3-23
and V3-30 gene segments were found to be the most frequently rearranged VH3 family
genes at the pro-B cell stage (Rao et. al., 1999). In B cell differentiation and
development, the pro B cell is a precursor B cell that has productively rearranged
VHDJH genes but has not as yet expressed the µ (mu) protein. For this reason, pro-B
cells are unaffected by selection mechanisms arising out of contact with antigen. In the
B cell lineage, pro-B cells that have successfully rearranged a productive VHDJH gene
may differentiate into pre-B cells which expresses the pre-B cell receptor consisting of
µ-surrogate light chain complex (Melchers et. al., 1993). Further differentiation takes
place through immature and mature B cells (with the disappearance of the pre-B cell
receptor), and the expression of surface immunoglobulin (sIgM) and IgD respectively.
Rao and colleagues reasoned that earlier observations indicating the preferential
rearrangement and over-representation of certain VH segments and families in the
repertoire were made from B cells that have already rearranged productive chains and
have already been committed to selection (De Wildt et. al., 1999; Kraj et. al., 1997;
Huang et. al., 1996). In their study, they demonstrated that even in pro-B cells that do
not express antigen receptors, the V3-23 and V3-30 gene segments were the most
frequently rearranged VHDJH segments representing about 20 % and 24 % respectively
among 760 VH3 family genes. The study showed that the repertoire is already biased
long before the expression of antigen receptors on the surface of the B cell (Rao et. al.,
1999).
The detection of solely VH3 Fabs (seven independent clones comprising six V3-23 and
one V3-30) in the library from the patient with systemic lupus erythematosus and
rheumatic fever does not seem to reflect an artifact. To make the library as diverse as
possible, the V genes from the patient were isolated using degenerate PCR primers that
can amplify all human VH germline genes (Kang et. al., 1991b).  To access the clonal
diversity of the library and to access that the library was not dominated by clones
arising from an artifact of preferential amplification of a few clones, 12 unselected
clones were analyzed by BstN1 restriction. BstN1 frequently cuts in the VH region but
only at 2 sites in the pComb3H vector. The restriction pattern which was confirmed by
sequencing of 5 unselected clones revealed that the library was heterogenous. Whereas
the IVIG library utilized only two VH3 family loci namely V3-23 and V3-30, the
immunoglobulins isolated from the unselected library used different VH3 family genes
namely 3-13, 3-23, 3-15, and one that has not as yet been assigned to a VH locus, as
well as a VH1 family segment 1-69, emphasizing that the unselected library from the
patient did not comprise VH genes solely from the V3-23 and V3-30 loci. Similarly,
sequencing of unselected clones from libraries studies in our laboratory showed no bias
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for a certain germline gene loci; rather a variety of different germline genes not
observed among the IVIG-bound Fabs have been observed (Leucht et. al., 2001;
Hoffmann et. al., 2000).
The normal/healthy immune system frequently produces autoantibodies, however
autoimmunity is a rare event. This implies autoimmunity results from a perturbation of
the control mechanisms (Potter and Capra, 1995). It has been observed that the germline
gene loci dominating the IVIG-selected Fabs (V3-23 and V3-30) were also frequently
utilized for coding other autoantibodies though it has not been established that only
limited VH segments could be used for autoantibodies (Matsuda et. al., 1993). For
example, the V3-30 sequence is homologous to RF-TS2, RF-SJ1 and RF-SJ2 cDNA for
rheumatoid factors (Pascual et. al., 1990). This same germline VH segment was 99.7 %
identical to cDNA for Kim4.6 autoantibody (Cairns et. al., 1989) which has DNA
binding activity. The V3-23 segment is identical to the anti-DNA autoantibody (18/2)
(Dersimonian et. al., 1987) and 30P1 cDNA found in fetal liver (Schroeder and Wang,
1990, Schroeder et. al., 1987). In addition, the V3-15 segment, which is the germline
gene of 20P1 cDNA expressed in fetal liver is 99.7 % identical to cDNA for 4B4, an
anti-Sm antibody encountered in systemic lupus erythematosus (Sanz et. al., 1989).
Matsuda et. al. (1993) hypothesized that the correlation between autoantibody VH genes
and the early repertoire VH, indicated that the preferred usage of autoantibody VH
segments in early stages of ontogeny may be due to positive selection by self-antigens.
Though autoantibodies displaying given specificities are most often associated with
different human autoimmune diseases, several studies in mice and humans have
demonstrated that healthy individuals regularly produce several autoantibodies encoded
by germline immunoglobulin variable regions with no somatic mutations. These
autoantibodies do not provoke autoimmune pathology, in contrast to patient-derived
autoantibodies that are highly specific for their respective autoantigens (Potter and
Capra, 1995; Hoffmann et. al., 2000). The presence of autoantibodies in the normal
immune system suggests that they may play some important physiological roles by
augmenting the opsonization of infectious agents and the clearance of immune
complexes and senescent cells. The importance of an autoreactive variable region gene
in the development of the humoral immune system was demonstrated in a study where it
was shown that a VH gene frequently expressed in fetal liver was homozygously deleted
in 20 % of patients with systemic lupus erythematosus and rheumatoid arthritis, but in
only 2 % of healthy controls. This germline gene, designated Humhv3005, belongs to
the V3-30 germline polymorphic gene variants, and encodes an amino acid sequence
identical to the 56P1 VH germline gene which is frequently expressed in fetal liver. The
hv3005 gene is also 99 % homologous to the 1.9III germline VH gene which in turn is
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identical to the heavy chain of the kim4.6 anti-DNA antibody.  Olee et. al. (1991)
contended that homeostasis of the early B cell repertoire is maintained through
interactions between autoreactive V genes and autoantigens, and subsequently through
an interconnecting network of idiotypes-antiidiotypes. Thus a complete deletion of a
cluster of developmentally important autoreactive V genes such as hv3005-like genes
may alter the humoral immune response to bacterial and/or viral infections resulting in
the overproduction of aberrant antibodies that may contribute to the initiation and/or
perpetuation of autoimmune diseases.
4.4 BINDING OF IVIG COMPARED TO KNOWN B CELL SUPERANTIGENS
The VH3 sequences expressed by the Fab phages isolated in this study utilized different
D and JH CDR3 region genes. The CDR3s were encoded by different D (D6-19, D4;
D2-8; D4-11; D6-25; D3-3; and D3-22) and JH (JH4b; JH3b; JH1; and JH6b) gene
segments, and the lengths of the CDR3 regions were also variable. These features of the
D and JH genes indicated that the CDR3 region was not crucial in binding by IVIG. The
interaction of IVIG with V3-23 and V3-30 from the VH3 gene family was also
demonstrated in a control study where the subjects were healthy individuals (Hoffmann
et. al., 2000). In this study, 21/27 (78 %) of Fabs bound by IVIG were derived from
VH3 gene family. Of note, 14/21 (66.6 %) of these VH3 Fabs were from  the V3-23 and
V3-30 loci which accounted for about 52 % (14/27) of the entire Fabs isolated. Hence
the selection of these  Fabs is linked to the preferential interaction of IVIG with V3-23
and V3-30. Thus, the results from Fischer, et. al. (1999); Jendreyko et. al. (1998);
Hoffmann et. al. (2000), and this current study reveal that the preferential interaction of
IVIG with Fabs from the V3-23 and V3-30/3-30.5 germline origins was not restricted to
the healthy status of the donor, neither to treatment with IVIG. In conclusion, the
observed interaction of IVIG with the Fabs was characteristic of binding of a B cell
superantigen. In this regard, we compared the specific IVIG binding of our Fabs with
the 2 best characterized B cell superantigens namely, staphylococcal protein A (SpA)
and HIV-1 gp120.
B cell superantigens are proteins that interact with B cell and T cell receptors as well as
immunoglobulins molecules outside the classical antigen binding sites (Silverman,
1997). They are potent activators of lymphocytes and have the capability of activating
more than 5 % of the naive lymphocyte pool (an enormous population) in contrast to
conventional peptide antigens that stimulate less than 0.01 %, representing a 500-fold
enhanced lymphocyte activation potential (White et. al., 1989). Staphylococcal protein
A (SpA) is a 42-kDa membrane protein of Staphylococcus aureus (Silverman, 1997).
SpA, secreted by nearly all known clinical isolates of S. aureus, enhances virulence of
the pathogen although the mechanisms have not been identified. SpA is a tandem of five
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extra-membrane domain proteins E, D, A, B, C and an additional transmembrane
domain named X. Each of the extramembrane domain has 58 - 61 amino acids and share
a primary amino acid homology of about 80 % with each other. SpA has two distinct
types of immunoglobulin binding specificities; one in the Fab portion of
immunoglobulins of the IgM, IgA, IgG, and IgE isotypes and the other in the Fc portion
of IgG1, IgG2, IgG3, and IgG4 immmunoglobulins (Potter et. al., 1997). Each
extramembrane domain is thought to be capable of mediating Fcγ binding. The Fcγ
binding property of Protein A is extensively utilized in purification and labeling of
proteins (Graille et. al., 2000). All five extramembrane domais have also been
demonstrated to show human Fab binding (Janssson et. al., 1998).
SpA specifically binds to antibodies from the human VH3 gene family but not
immunoglobulins from other VH families (Silverman, 1997). Immunoglobulins bound
specifically by SpA share conserved sequences in FR1, FR3 and the C-terminal portion
of CDR2 outside the H2 loop unique only to the VH3 gene family. Kirkham and
Schroeder (1994), suggested that the C-terminal portion of CDR2 (from the VH3 family
that correlates with SpA binding activity) is an invariant VH3 family-specific stretch
sequence which could be more appropriately designated as part of the FR3 subdomain.
Studies with three different phage display antibody libraries demonstrated that multiple
rounds of panning on SpA resulted in selection of VH3 Fabs that were encoded by the
V3-23 gene (Silverman, 1998). Within the human genome, the V3-23 gene is closest to
the consensus sequence of all inherited human VH3 genes, and it encodes for VH regions
that contain one of the most highly conserved VH FR1/FR3 surfaces (Schroeder et. al.,
1990). Of all VH3 antibodies with binding to SpA that have so far been evaluated, the
V3-23 derived antibodies have the strongest binding interactions with the native SpA
(Silverman et. al., 1997). The crystal structure of domain D of SpA complexed to a V3-
30 derived Fab has confirmed earlier studies that the critical amino acids necessary for
binding are located in the FR1, FR3 and CDR2 of the VH3 immunoglobulin molecule
(Graille et. al., 2000; Potter et. al., 1998). Silverman and colleagues investigating the
unconventional nature of SpA binding demonstrated that 13 VH3 amino acid residues in
FR2/FR3 and CDR2 are essential for SpA binding (Graille et. al., 2000; Cary et. al.,
2000). Among the 13 VH residues implicated as SpA contacts, VH3 genes include
frequent germline sequence variations only at position 57. This position is not a core
position and substitution of isoleucine (I) and threonine (T) for lysine (K) are
permissive for SpA binding. The other 12 remaining VH residues which are highly
conserved in the VH3 family have been found to be in direct contact with domain D of
SpA. By comparison, other nonbinding germline VH family genes have been found to
contain two or more residue differences at the 13 VH positions identified as SpA
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contacts (Cary et. al., 2000). A detailed structural study by Graille et. al. (2000)
identified 7 core residues among the 13 VH contact residues: arginine/lysine (R/K)-19,
glycine (G)-65, arginine (R)-66, threonine (T)-68, serine (S)-70, glutamine (Q)-81, and
asparagine (N)-82a. These core of 7 VH residues constitutes the structural motif of SpA
binding, and conveys the restricted specificity for VH3-encoded immunoglobulin and
their homologoues.  All Fabs isolated here expressed these 13 VH amino acid residues
and importantly, the 7 core residues as well. However, their binding to SpA varied in
intensity. The observed binding differences could be due to subtle conformational
variations which could be permissive for some immunoglobulins and not others.
Karray et. al. (1998), observed that gp120 immunoglobulin binders are highly sensitive
to mutation. They demonstrated that V3-30 gene-encoded immunoglobulins with less
than 96 % homology to germline genes lose the capacity to bind gp120, thus suggesting
that hypermutation may have an adverse effect on gp120 binding. This inverse
correlation between the degree of somatic mutation and gp120 binding is similar to the
reported binding pattern described for SpA. V gene hypermutation associated with
somatic selection of the B cell repertoire by exogenous antigens apparently often results
in a loss of that B cell superantigen’s binding capacity. The B cell receptor has a
distinctive feature of undergoing somatic hypermutation, which influences the
representation of superantigen binding B cell receptors in the somatic immune
repertoire. Germline encoded V region structures demonstrate higher affinities (and
avidities) in immature animals and in naive lymphocyte subsets than in IgG bearing B
cells (Silverman et. al., 1997). While only about 80 - 85 % of VH3 IgMs from adult
sources bind SpA, SpA binding activity has been demonstrated for every non-mutated
VH3 immunoglobulin that has so far been tested (Hillson et. al., 1993 as reviewed in
Silverman, 1997). Also, the frequency of superantigen binding in IgG populations
which generally show greater levels of hypermutation is much lower than for IgM
populations (Sasano et. al., 1993). Though many immunoglobulins (VH3 family) that
have undergone class switch and somatic mutation lose the ability to bind SpA, a
substantial number of these antibodies still bind SpA. Silverman (1997) reported that at
least 16 of the 22 (72 %) known functional VH3 germline encoded genes have SpA
binding activity while Sasano et. al. (1993) demonstrated that 60 % of VH3 Fab
fragments had SpA-binding activity. Since some somatically-mutated VH3 encoded
antibodies can bind SpA, both the position and nature of the mutations affect SpA
binding (Potter et. al., 1997).
Thus, hypermutation somewhat adversely affects the frequency and avidity of VH3
mediated SpA binding. However, from our results, the presence of mutations alone may
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not account for the observed SpA binding pattern exhibited by the Fab phages. Fab
phage SH51, maintaining all the residues known for SpA binding and with an R/S ratio
greater than 2.9 showed strong interaction with SpA, whilst Fab phages SH21 and SH58
with 99.6 % and 99.3 % homologies to the V3-23 germline gene, respectively, did not
show any appreciable binding to SpA. SH21 has an extremely long VH CDR3 (17
amino acids), which could result in structural interference with binding to SpA. Could
the association of  different light chains influence these VH3 non-SpA binding
interactions? Potter and Capra (1995), reported the loss of a mouse monoclonal
antibody LC1 reactivity against human monoclonal antibody with rheumatoid factor
reactivity when some light chains were paired with an LC1 reactive heavy chain. LC1
detects a cross-reactive idiotope on the heavy chain of many non-pathogenic IgM
antibodies and monoclonal IgM autoantibodies, many of which exhibit rheumatoid
factor reactivity. The loss of LC1 reactivity indicates that the light chain influenced the
availability of the LC1 determinant and provides another mechanism, other than
mutation to explain the loss of an heavy chain isotype. The light chain could also
provide conformational variations which could be non-permissive for some
immunoglobulins and thus influence its binding abilities. In certain cases however, light
chain pairing may influence the capacity of SpA to bind VH3 containing heavy chains
(Domiati-Saad and Lipsky, 1997).
The critical residues for binding gp120 to VH3 gene families, though not so well
defined, (Neshat et. al., 2000) may be in overlapping regions to that of SpA. On the
whole, our IVIG Fabs showed weak binding to gp120 whilst stronger reactivities on
SpA were recorded for some clones. The observed binding differences between SpA
and gp120 for the Fab phages could be that SpA and gp120 target different sites on VH3
immunoglobulins, some of these contact sites partially overlap though (Karray et. al.,
1998). In addition, none of the two superantigens tested in this study (SpA and gp120)
was able to compete with IVIG in binding to the Fabs, indicating that at least some of
the contact residues on IVIG must be different from those for SpA and gp120.
Delineating the exact mechanism(s) of binding of IVIG to V3-23 and V3-30 Fabs is an
enormous task, granted the huge variety of immunoglobulins present in the IVIG pool.
As a solution, our IVIG-selected Fabs may now be used to clone antibodies
representative of this IVIG subfraction from a healthy donor library. This will enable
the study of the structural basis for recognition and possible regulatory influence on the
B cell repertoire during normal development and disease (Osei et. al., 2000).
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4. 5 SUMMARY AND CONCLUSION
The beneficial therapeutic effects of IVIG are well documented, but the underlying
molecular mechanisms are not fully understood. Recent investigations from our
laboratory into the molecular analysis of Fabs bound by IVIG from patients suffering
from autoimmune thrombocytopenia revealed that the most frequently selected Fabs
originated from the V3-23 and V3-30 VH germline genes. A subsequent study with IgG
and IgM phage display libraries from a healthy donor also demonstrated a preferential
reactivity of IVIG to Fabs of V3-23 and V3-30 origin. That study revealed that the
unique reactivity of IVIG to Fabs of these two VH gene loci was not restricted to the
autoimmune nature of the donors, neither to previous treatment with IVIG. One of the
thrombocytopenia patients developed lupus. This study was undertaken to study the
molecular interaction of IVIG  with antibodies selected from a patient suffering from
systemic lupus erythematosus and rheumatic fever using phage display  technology, and
to compare the results with the previous studies.
Twenty-three Fabs representing seven independent clones were isolated. In contrast to
ITP-derived clones, none of the Fabs selected in this study reacted with platelets. The
Fab phages bound by IVIG were sequenced in order to determine their VH gene usage
and clonal relatedness. V3-23 and V3-30 VH genes were found to be exclusively
utilized by the Fab phages bound by IVIG. Moreover, different CDR3 regions including
different D and JH gene segments were observed to be used by these Fabs. The results
further showed that the binding of IVIG to the Fabs was independent of the light chain
since different light chains were observed to be associated with the VH3
immunoglobulins. Detailed sequence analysis of the Fabs revealed the presence of
amino acid residues at positions within FR1, FR3, and the 3’ end of CDR2 that are
known to be contacted by the B cell superantigen Staphylococcus protein A (SpA).
Some of the Fabs were shown to bind strongly to SpA, but there was no correlation with
the binding-intensity to IVIG. Some bound very weakly to HIV gp120, another B cell
superantigen. This study, together with previous results,  suggests that a subset of IVIG
may function as a B cell superantigen that may significantly shape the B cell repertoire.
The binding mechanism appears to be similar but not identical to the other tested B cell
superantigens.
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4.6 ZUSAMMENFASSUNG UND SCHLUSSFOLGERUNG
Therapeutische Erfolge von IVIG sind gut dokumentiert, aber die zu Grunde liegenden
molekularen Mechanismen sind noch nicht vollständig erforscht. Molekulare Analysen
unseres Labors über die Interaktion von IVIG mit Fabs von Patienten, die an einer
autoimmunen Thrombozytopenie (ITP) leiden zeigten, dass die am häufigsten
selektierten Fab von den V3-23 und V3-30 VH-Keimbahngenen abstammten. Eine
weitere Studie mit IgG und IgM Phagen-Display Bibliotheken von einem gesunden
Spender zeigten ebenfalls eine bevorzugte Reaktivierung von IVIG mit Fabs vom
Ursprung der V3-23 und V3-30 Gene. Es konnte gefolgert werden, dass diese
Interaktion von IVIG mit Fabs von diesen zwei VH-Genen weder alleine auf den
Gesundheitsstatus des Spenders zurückzuführen war, noch auf eine zuvor erfolgte
Behandlung mit IVIG. Diese Dissertation wurde unter Verwendung der Phagen-Display
Technologie unternommen, um die molekulare Interaktion von IVIG mit Antikörpern
zu erforschen, die von einem Patienten kloniert wurden, der an einem systemischen
Lupus erythematodes und rheumatischem Fieber leidet. Die Resultate waren mit den
früheren Studien zu vergleichen, insbesondere mit den Daten eines Patienten, der zu der
ITP einen Lupus entwickelte.
23 Fabs, welche 7 unabhängige Klone repräsentierten, wurden isoliert. Im Gegensatz zu
von Patienten mit ITP abstammenden Klonen reagierte keines von den in dieser Studie
selektierten Fabs mit Thrombozyten. Die über IVIG gebundene Fab-Phagen stammten
hierbei ausschließlich von den V3-23 und V3-30 VH-Genen ab. Darüber hinaus wurde
beobachtet, dass von diesen Fabs verschiedene CDR3 Regionen einschließlich
verschiedenen D- und JH-Gensegmenten benutzt wurden. Die Ergebnisse zeigten
weiterhing, dass die Bindung von IVIG an die Fabs unabhängig von der Leichten Kette
war. Ihrem Keimbahngen-Ursprung entsprechend hatten die Fabs Aminosäuren an
Positionen in den FR1, FR3 und im 3’-Ende von CDR2, die dafür bekannt sind, dass sie
für die Bindung des B-Zell-Superantigens Staphylococcus Protein A (SpA) essentiell
sind. Es wurde gezeigt, dass sich zwar einige von den Fabs stark an SpA banden, aber
keine Korrelation in der Intensität zur Bindung mit IVIG vorlag. Einige Fabs zeigten
eine schwache Bindung an HIV gp120, einem anderen B-Zell-Superantigen.
Zusammenfassend lässt sich aus der vorliegenden Studie und den vorherigen
Ergebnissen schließen, dass ein Anteil von IVIG wie ein B-Zellen Superantigen
funktionieren könnte, das für die Bildung und Regulation des normalen B-Zellen
Repertoires wichtig ist. Der Bindungsmechanismus scheint ähnlich, aber nicht identisch
mit dem der anderen getesteten B-Zellen-Superantigene zu sein.
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